[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 199
1. Gérard J, Berdin B, Portier G, Godon A, Tessier-Marteau A, Geneviève F, Zandecki M: [Bone marrow necrosis in two patients with neoplastic disorders]. Ann Biol Clin (Paris); 2007 Nov-Dec;65(6):636-42
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Nécrose médullaire chez deux patients atteints de maladies cancéreuses.
  • Bone marrow necrosis is defined by extensive necrosis of the myeloid tissue and bone marrow stroma.
  • Diagnosis is done on characteristic cytological pattern of the bone marrow aspiration and/or biopsy.
  • An haematological malignancy was suspected after observation of a few peripheral blood blast cells, but necrosis was found on the bone marrow aspiration and could not lead to further haematological diagnosis.
  • Within next days, the white blood cell count and the number of blasts increased, leading to the diagnosis of acute monoblastic leukaemia.
  • The second patient, aged 28, has been hospitalized for severe bleeding a few days after the diagnosis of a metastatic gastric tumour.
  • According to literature, bone marrow necrosis is in most instances secondary to either an haematological malignancy (60%) or to a solid tumour (30%), but only at times observed with a non-malignant disorder.
  • Bone pain, fever, cytopenias and elevated serum lactic dehydrogenase and alkaline phosphatase are frequently reported, but are mostly non specific of the diagnosis in these malignant conditions.
  • Examination of the bone marrow leads to the diagnosis: cells are pycnotic, scarcely recognizable in a background of amorphous extracellular eosinophilic proteinaceous material, and histology shows disappearance of fat spaces with preservation of the bone tissue.
  • Tissue hypoxemia due to microcirculation failure may be the main mechanism leading to the necrosis, whatever the related disorder.
  • Supportive care together with specific therapy of the causal disease must be started promptly.
  • [MeSH-major] Bone Marrow / pathology. Leukemia, Monocytic, Acute / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Bone marrow necrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18039608.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


2. Hsaini Y, Allam W, Errihani H: Polyradiculoneuritis revealing an acute monoblastic leukemia 5. Pan Afr Med J; 2010;5:17
Genetic Alliance. consumer health - Acute Monoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polyradiculoneuritis revealing an acute monoblastic leukemia 5.
  • Acute polyradiculoneuritis has been frequently reported in association with malignant disorders, especially those of the lymphoid system.
  • To date, there have been no reported cases of acute monoblastic leukemia associated with this polyradiculopathy.
  • The authors tell us about a very rare case of leukemia presenting as acute monoblastic leukemia 5 (AML5) in a 28 years old patient from Morocco.
  • [MeSH-major] Leukemia, Monocytic, Acute / diagnosis. Polyradiculoneuropathy / etiology
  • [MeSH-minor] Adult. Diagnosis, Differential. Electromyography. Fatal Outcome. Histocytochemistry. Humans. Morocco

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol Neurosurg Psychiatry. 1993 Aug;56(8):936-7 [8350119.001]
  • [Cites] Rev Neurol (Paris). 2005 Sep;161(8-9):823-8 [16244564.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 1996 Dec;58(6):435-8 [9068211.001]
  • [Cites] Brain. 1995 Oct;118 ( Pt 5):1233-45 [7496783.001]
  • (PMID = 21293744.001).
  • [ISSN] 1937-8688
  • [Journal-full-title] The Pan African medical journal
  • [ISO-abbreviation] Pan Afr Med J
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Uganda
  • [Other-IDs] NLM/ PMC3032619
  • [Keywords] NOTNLM ; Guillain-Barre / Morroco / acute monoblastic leukemia / polyradiculoneuritis
  •  go-up   go-down


3. Prihirunkit K, Narkkong NA, Apibal S: Acute monoblastic leukemia in a FeLV-positive cat. J Vet Sci; 2008 Mar;9(1):109-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute monoblastic leukemia in a FeLV-positive cat.
  • Testing for antibodies specific to feline leukemia virus (FeLV) was positive, and FeLV nucleic acid was confirmed by nested polymerase chain reaction.
  • Base on cytochemistry and ultrastructure, the cat was diagnosed with acute monoblastic leukemia.
  • [MeSH-major] Cat Diseases / diagnosis. Cat Diseases / virology. Leukemia Virus, Feline / isolation & purification. Leukemia, Monocytic, Acute / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Vet Pathol. 1985 Sep;22(5):456-62 [3863358.001]
  • [Cites] Vet Pathol. 1986 Mar;23(2):103-9 [3962077.001]
  • [Cites] Blood. 1993 May 15;81(10):2585-90 [8387834.001]
  • [Cites] Vet Clin North Am Small Anim Pract. 1981 May;11(2):321-47 [7032049.001]
  • [Cites] Leukemia. 2005 Jun;19(6):953-64 [15815718.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2665-9 [11289145.001]
  • [Cites] Vet Clin Pathol. 2002;31(3):116-26 [12189597.001]
  • [Cites] Arch Virol. 1997;142(2):323-32 [9125046.001]
  • (PMID = 18296895.001).
  • [ISSN] 1229-845X
  • [Journal-full-title] Journal of veterinary science
  • [ISO-abbreviation] J. Vet. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2839105
  •  go-up   go-down


Advertisement
4. Kim J, Park TS, Song J, Lee KA, Lee SG, Cheong JW, Choi JR: Tetrasomy 8 in a patient with acute monoblastic leukemia. Korean J Lab Med; 2008 Aug;28(4):262-6
Genetic Alliance. consumer health - Acute Monoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tetrasomy 8 in a patient with acute monoblastic leukemia.
  • Trisomy 8 is one of the most frequent numerical chromosomal abnormalities observed in hematological malignancies, whereas tetrasomy 8 is a clonal aberration seen mainly in myeloid disorders such as acute myelod leukemia (AML) and myelodysplastic syndromes.
  • In contrast to trisomy 8, tetrasomy 8 is a rare chromosomal aberration, in that only 17 reported AML cases with isolated tetrasomy 8 have been documented.
  • Interestingly, the majority of reported cases were associated with monocytic-lineage leukemias.
  • According to recent reports, tetrasomy 8 is regarded as a poor prognostic factor, and most patients having this abnormality relapsed and died within 1 yr.
  • Here, we report a patient with acute monoblastic leukemia having tetrasomy 8 and a very aggressive disease course.
  • [MeSH-major] Aneuploidy. Chromosomes, Human, Pair 8. Leukemia, Monocytic, Acute / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18728374.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


5. Takahashi T, Tsukuda H, Kimura H, Yoshimoto M, Tsujisaki M: Extramedullary relapse of AML with t(9;11)(p22;q23) associated with clonal evolution from trisomy 8 into tetrasomy 8. Intern Med; 2010;49(5):447-51
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramedullary relapse of AML with t(9;11)(p22;q23) associated with clonal evolution from trisomy 8 into tetrasomy 8.
  • This report describes a patient with extramedullary relapse of acute myeloid leukemia (AML) without involving bone marrow.
  • A 57-year-old man was diagnosed as having acute monoblastic leukemia with t(9;11)(p22;q23) and trisomy 8.
  • To our knowledge, this is the first case report of clonal evolution associated with the development of myeloid sarcoma as a relapse in AML.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 8 / genetics. Chromosomes, Human, Pair 9 / genetics. Leukemia, Myeloid, Acute / genetics. Sarcoma, Myeloid / diagnosis. Sarcoma, Myeloid / genetics. Trisomy / genetics

  • Genetic Alliance. consumer health - Chromosome 9, Trisomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20190481.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Gallipoli P, Leach M: Gingival infiltration in acute monoblastic leukaemia. Br Dent J; 2007 Nov 10;203(9):507-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gingival infiltration in acute monoblastic leukaemia.
  • Acute myeloid leukaemias (AML) are aggressive haematopoietic neoplasms that, if untreated, can lead to death within days.
  • Up to 40% of presenting patients show evidence of extramedullary involvement (EMI) at diagnosis.
  • EMI is reportedly most prevalent in myelo-monoblastic and monoblastic subtypes of AML (M4 and M5 according to FAB classification) and can present as leukaemic infiltrates in many sites including gingival enlargement and mucosal and skin nodules.
  • [MeSH-major] Gingiva / pathology. Gingival Overgrowth / etiology. Leukemia, Monocytic, Acute / pathology. Leukemic Infiltration

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17992229.001).
  • [ISSN] 1476-5373
  • [Journal-full-title] British dental journal
  • [ISO-abbreviation] Br Dent J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Athanasiadis GI, Pfab F, Braun-Falco M, von Bubnoff N, Fend F, Ring J, Ollert M: Subcutaneous nodules revealing acute monoblastic leukaemia (FAB type M5A). J Eur Acad Dermatol Venereol; 2007 Oct;21(9):1296-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous nodules revealing acute monoblastic leukaemia (FAB type M5A).
  • [MeSH-major] Leukemia, Monocytic, Acute / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biopsy. Combined Modality Therapy. Diagnosis, Differential. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17894748.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


8. Bacchetta J, Douvillez B, Warin L, Girard S, Pagès MP, Rebaud P, Bertrand Y: [Blueberry Muffin Baby and spontaneous remission of neonatal leukaemia]. Arch Pediatr; 2008 Aug;15(8):1315-9
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Blueberry Muffin Baby and spontaneous remission of neonatal leukaemia].
  • Blueberry Muffin baby is a rare neonatal skin disorder.
  • We report on a newborn presenting with Blueberry Muffin syndrome and an adrenal mass which lead to the diagnosis of neuroblastoma.
  • Actually, it corresponded to an acute monoblastic leukaemia with an adrenal localization and a cerebrospinal fluid involvement.
  • Leukaemia should always be considered in such patients, even in the absence of blasts on white blood cells count and bone marrow examination, as in this patient.
  • [MeSH-major] Leukemia, Myeloid, Acute. Skin Diseases / congenital
  • [MeSH-minor] Diagnosis, Differential. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Remission, Spontaneous. Time Factors

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18595669.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


9. Pawarode A, Baer MR, Padmanabhan S, Wallace PK, Barcos M, Sait SN, Block AW, Wetzler M, Battiwalla M: Simultaneous presentation of acute monoblastic leukemia and mantle cell lymphoma: case report and review of the literature. Leuk Lymphoma; 2005 Dec;46(12):1813-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous presentation of acute monoblastic leukemia and mantle cell lymphoma: case report and review of the literature.
  • This paper reports a 73-year old woman with simultaneous presentation of acute monoblastic leukemia (acute myeloid leukemia (AML), French-American-British (FAB) type M5a) and mantle cell lymphoma.
  • The patient received infusional cytarabine, daunorubicin and etoposide chemotherapy, with complete remission of both the AML and the mantle cell leukemia.
  • To the authors' knowledge, this is the first report of simultaneous presentations of AML, FAB M5a and mantle cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Monocytic, Acute / complications. Lymphoma, Mantle-Cell / complications


10. Demircioğlu F, Oren H, Yilmaz S, Arslansoyu S, Eren S, Irken G: Chemotherapy-induced acral erythema in a pediatric patient with acute monoblastic leukemia. Pediatr Hematol Oncol; 2008 Apr-May;25(3):211-5
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy-induced acral erythema in a pediatric patient with acute monoblastic leukemia.
  • The authors present a case of acral erythema in a young patient with acute monoblastic leukemia to emphasize this high-dose chemotherapy-induced side effect, which is rarely seen in children and is usually self-limited.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Erythema / chemically induced. Leukemia, Monocytic, Acute / complications

  • Genetic Alliance. consumer health - Acute Monoblastic Leukemia.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18432504.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


11. Prayongratana K, Kulpraneet M, Panichchob P, Tantisiriwat W: Acute monoblastic leukemia with t(10;11)(p12;q23) presenting with pulmonary involvement: a case report and literature review. J Med Assoc Thai; 2008 Apr;91(4):559-63
Hazardous Substances Data Bank. CASPOFUNGIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute monoblastic leukemia with t(10;11)(p12;q23) presenting with pulmonary involvement: a case report and literature review.
  • A forty-three-year-old Thai man presented with acute fever and dyspnea for one week with bilateral patchy infiltration, pancytopenia with monoblast.
  • Bone marrow study was consistent with acute monoblastic leukemia.
  • Lung lesions rapidly progressed to acute respiratory failure, which required intubation.
  • Bronchoscopy with bronchoalveolar lavage revealed monotonous monoblast infiltration.
  • This may be due to the low incidence of leukemic infiltration of acute leukemia patients, which is 0.48% and 3.06% in acute myeloid leukemia and acute monoblastic leukemia, respectively.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Monocytic, Acute / pathology. Lung Neoplasms / secondary

  • Genetic Alliance. consumer health - Acute Monoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18556867.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antifungal Agents; 0 / Antimetabolites, Antineoplastic; 0 / Echinocandins; 0 / Pyrimidines; 0 / Triazoles; 04079A1RDZ / Cytarabine; F0XDI6ZL63 / caspofungin; JFU09I87TR / Voriconazole; ZRP63D75JW / Idarubicin
  • [Number-of-references] 22
  •  go-up   go-down


12. Oliveira FM, Lucena-Araújo AR, Leite-Cueva SD, Santos GA, Rego EM, Falcão RP: Segmental amplification of MLL gene associated with high expression of AURKA and AURKB genes in a case of acute monoblastic leukemia with complex karyotype. Cancer Genet Cytogenet; 2010 Apr 1;198(1):62-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Segmental amplification of MLL gene associated with high expression of AURKA and AURKB genes in a case of acute monoblastic leukemia with complex karyotype.
  • We report a case of acute monoblastic leukemia showing a jumping translocation with the MLL gene in a 17-year-old male.
  • Jumping translocation with the MLL gene rearrangement is an uncommon phenomenon reported in leukemia cytogenetics.
  • [MeSH-minor] Adolescent. Aurora Kinase A. Aurora Kinase B. Aurora Kinases. Chromosome Aberrations. Gene Amplification. Humans. Leukemia, Monocytic, Acute / genetics. Male. Myeloid-Lymphoid Leukemia Protein / genetics. Translocation, Genetic. Up-Regulation

  • Genetic Alliance. consumer health - Acute Monoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20303016.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.7.11.1 / AURKA protein, human; EC 2.7.11.1 / AURKB protein, human; EC 2.7.11.1 / Aurora Kinase A; EC 2.7.11.1 / Aurora Kinase B; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


13. Stasik C, Ganguly S, Cunningham MT, Hagemeister S, Persons DL: Infant acute lymphoblastic leukemia with t(11;16)(q23;p13.3) and lineage switch into acute monoblastic leukemia. Cancer Genet Cytogenet; 2006 Jul 15;168(2):146-9
Genetic Alliance. consumer health - Acute Monoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infant acute lymphoblastic leukemia with t(11;16)(q23;p13.3) and lineage switch into acute monoblastic leukemia.
  • Rearrangements of the mixed-lineage leukemia (MLL) gene have been associated with a poor prognosis in infant acute lymphoblastic leukemia (ALL).
  • Previously, MLL translocations involving the CREP-binding protein (CREBBP) gene at chromosome band 16p13.3 have primarily been reported in treatment-related acute myeloid leukemia, after chemotherapy for other primary malignancies using topoisomerase II inhibitors.
  • We report a case of de novo infant ALL with t(11;16)(q23;p13.3).
  • After chemotherapy, this patient developed an acute monoblastic leukemia (M5b) with retention of the t(11;16)(q23;p13.3), indicating that this is a lineage switch of the original leukemic clone.
  • [MeSH-major] Cell Lineage. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 16 / genetics. Leukemia, Monocytic, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16843104.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Kurosawa H, Tsuboi T, Shimaoka H, Okuya M, Nakajima D, Matsunaga T, Hagisawa S, Sato Y, Sugita K, Eguchi M: [Long-term remission in an acute monoblastic leukemia patient with down syndrome after cord blood transplantation]. Rinsho Ketsueki; 2005 Apr;46(4):274-7
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term remission in an acute monoblastic leukemia patient with down syndrome after cord blood transplantation].
  • A 4-year-old boy with Down syndrome (DS) was diagnosed as having acute monoblastic leukemia (AML-M5a).
  • After 2 courses of induction therapy using an AML 99-Down protocol failed to obtain complete remission, the patient received cord blood transplantation from an HLA-matched donor (CBT) following a conditioning regimen comprising total body irradiation and cyclophosphamide.
  • Only cyclosporin A was used for graft-versus-host disease prophylaxis.
  • Stem cell transplantation may not be indicated for AML patient with DS in first remission, who display a high rate of life-threatening and fatal toxicity on therapy.
  • This patient remained well controlled in complete remission for 4 years, representing a rare case of DS with chemotherapy-resistant AML successfully treated with a CBT.
  • [MeSH-major] Cord Blood Stem Cell Transplantation. Down Syndrome / complications. Leukemia, Monocytic, Acute / therapy
  • [MeSH-minor] Child, Preschool. Cyclosporine / administration & dosage. Graft vs Host Disease / prevention & control. Humans. Male. Remission Induction. Time Factors. Transplantation Conditioning. Treatment Outcome


15. Yamada R, Horikawa K, Ishihara S, Hoshino K, Kawaguchi T, Iyama K, Mitsuya H, Asou N: Successful treatment of Aspergillus liver abscesses in a patient with acute monoblastic leukemia using combination antifungal therapy including micafungin as a key drug. Int J Hematol; 2010 May;91(4):711-5
MedlinePlus Health Information. consumer health - Hepatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of Aspergillus liver abscesses in a patient with acute monoblastic leukemia using combination antifungal therapy including micafungin as a key drug.
  • In intensive chemotherapy for leukemia, invasive aspergillosis resulting in death is infrequently observed.
  • Herein, we report a case of Aspergillus liver abscesses in a patient with acute monoblastic leukemia.
  • Therefore, our clinical experience suggests that the serum test is useful for the rapid diagnosis of invasive aspergillosis, especially in deep tissues, and that combination antifungal therapy with micafungin should be considered when initial monotherapy for fungal infection shows an insufficient effect.
  • [MeSH-major] Antifungal Agents / administration & dosage. Aspergillosis / drug therapy. Echinocandins / administration & dosage. Hepatitis / drug therapy. Leukemia, Monocytic, Acute / complications. Lipopeptides / administration & dosage. Liver Abscess / drug therapy

  • Genetic Alliance. consumer health - Acute Monoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 2008 Feb 1;46(3):327-60 [18177225.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):764-71 [10072411.001]
  • [Cites] Ann Pharmacother. 2001 Jun;35(6):720-9 [11408991.001]
  • [Cites] Ann Hematol. 1997 Jul-Aug;75(1-2):9-16 [9322678.001]
  • [Cites] Acta Biomed. 2006;77 Suppl 2:10-3 [16918060.001]
  • [Cites] Cancer. 2007 Dec 15;110(12 ):2740-6 [17941026.001]
  • [Cites] J Clin Microbiol. 2004 Jun;42(6):2733-41 [15184460.001]
  • [Cites] Clin Vaccine Immunol. 2008 Oct;15(10):1625-8 [18667632.001]
  • [Cites] Haematologia (Budap). 2001;31(1):73-80 [11345409.001]
  • [Cites] Clin Infect Dis. 2008 Mar 15;46(6):878-85 [18260755.001]
  • [Cites] J Infect. 2006 Nov;53(5):337-49 [16678903.001]
  • [Cites] Lancet. 2003 Oct 4;362(9390):1142-51 [14550704.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1068-75 [16885047.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1025-32 [12569602.001]
  • [Cites] Cancer. 1975 Dec;36(6):2271-6 [1060508.001]
  • [Cites] Drug Resist Updat. 2003 Aug;6(4):197-218 [12962685.001]
  • [Cites] Clin Infect Dis. 2007 Feb 15;44(4):531-40 [17243056.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Sep;25(9):732-4 [12972810.001]
  • [Cites] Clin Infect Dis. 2002 Jan 1;34(1):7-14 [11731939.001]
  • [Cites] Haematologica. 2001 Aug;86(8):862-70 [11522544.001]
  • [Cites] Clin Pharmacokinet. 2006;45(7):649-63 [16802848.001]
  • [Cites] Clin Infect Dis. 2000 Nov;31(5):1253-7 [11073760.001]
  • [Cites] J Clin Pharmacol. 2005 Oct;45(10):1145-52 [16172179.001]
  • [Cites] J Clin Pathol. 1960 Sep;13:396-413 [13707576.001]
  • [Cites] Clin Infect Dis. 2004 Sep 15;39(6):797-802 [15472810.001]
  • [Cites] J Infect Dis. 2006 Oct 1;194(7):1008-18 [16960790.001]
  • [Cites] Ann Hematol. 2006 Sep;85(9):621-3 [16758192.001]
  • [Cites] Am J Hematol. 2001 Dec;68(4):231-6 [11754411.001]
  • [Cites] Clin Infect Dis. 2003 Mar 1;36(5):630-7 [12594645.001]
  • (PMID = 20352380.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Lipopeptides; R10H71BSWG / micafungin
  •  go-up   go-down


16. Kameoka J, Horiuchi T, Miyamura K, Miura I, Okuda M, Nomura J, Hirokawa M, Sawada K, Sasaki T: [Acute monoblastic leukemia with tetrasomy 8]. Rinsho Ketsueki; 2006 Aug;47(8):770-6
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute monoblastic leukemia with tetrasomy 8].
  • Tetrasomy 8 is a rare chromosomal abnormality in acute leukemia, and it has recently been considered as a poor prognostic factor.
  • The patient was diagnosed as having AML (M5a), and treatment with daunorubicin (70 mg x 5 days) and cytosine arabinoside (150 mg x 7 days) resulted in a complete remission.
  • Her clinical course was almost uneventful except for a phlegmon in the right leg, but on day 49 a relapse occurred, and she died of acute renal failure on day 73.
  • This case strongly illustrates the characteristic of tetrasomy 8 as a poor prognostic factor in acute leukemia.
  • [MeSH-major] Aneuploidy. Chromosome Aberrations. Chromosomes, Human, Pair 8 / genetics. Karyotyping. Leukemia, Monocytic, Acute / genetics

  • Genetic Alliance. consumer health - Acute Monoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16986717.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


17. Balwierz W, Chełmecka-Hanusiewic L, Klekawka T, Wójcik B, Kowalczyk JR, Ksiazek T: [Complete autologous bone marrow recovery after allogeneic stem cell transplantation in a child with acute monoblastic leukemia]. Przegl Lek; 2010;67(6):425-6
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete autologous bone marrow recovery after allogeneic stem cell transplantation in a child with acute monoblastic leukemia].
  • [Transliterated title] Pełna odnowa autologiczna szpiku kostnego po alloprzeszczepieniu u dziewczynki z ostra białaczka monoblastyczna.
  • We present a case of autologous bone marrow recovery after allogeneic hematopoietic stem cell transplantation (HSCT) in a 7-year old girl who was treated due to acute myelocytic leukemia.
  • Presented case constitutes an exceptional clinical situation and it indicates that diagnosis of leukemia relapse should be cautiously considered once the autologous bone marrow recovery is observed after allogeneic HSCT.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Monocytic, Acute / therapy

  • Genetic Alliance. consumer health - Acute Monoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21344774.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


18. Douet-Guilbert N, Morel F, Le Bris MJ, Sassolas B, Giroux JD, De Braekeleer M: Rearrangement of MLL in a patient with congenital acute monoblastic leukemia and granulocytic sarcoma associated with a t(1;11)(p36;q23) translocation. Leuk Lymphoma; 2005 Jan;46(1):143-6
Genetic Alliance. consumer health - Acute Monoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rearrangement of MLL in a patient with congenital acute monoblastic leukemia and granulocytic sarcoma associated with a t(1;11)(p36;q23) translocation.
  • We report here a newborn girl who had disseminated intravascular coagulation and cutaneous tumors (granulocytic sarcomata) in whom a diagnosis of acute myeloblastic leukemia (AML) FAB-M5 was made.
  • Since the diagnosis was made at birth, this implies that the MLL rearrangement and the onset of the disease occurred in utero.
  • To the best of our knowledge, this is the first report of a case of congenital AML with GS arising in a patient with proven MLL rearrangement.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 11 / genetics. DNA-Binding Proteins / genetics. Leukemia, Monocytic, Acute / congenital. Leukemia, Monocytic, Acute / genetics. Proto-Oncogenes / genetics. Sarcoma, Myeloid / genetics. Transcription Factors / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Female. Gene Rearrangement / genetics. Histone-Lysine N-Methyltransferase. Humans. Infant, Newborn. Infant, Premature. Myeloid-Lymphoid Leukemia Protein. Pregnancy. Pregnancy Complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621793.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / Transcription Factors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  • [Number-of-references] 32
  •  go-up   go-down


19. Mo J, Lampkin B, Perentesis J, Poole L, Bao L: Translocation (8;18;16)(p11;q21;p13). A new variant of t(8;16)(p11;p13) in acute monoblastic leukemia: case report and review of the literature. Cancer Genet Cytogenet; 2006 Feb;165(1):75-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocation (8;18;16)(p11;q21;p13). A new variant of t(8;16)(p11;p13) in acute monoblastic leukemia: case report and review of the literature.
  • A complex three-way t(8;18;16)(p11;q21;p13) was detected in a 15-month-old patient with acute myeloid leukemia (AML).
  • The patient had typical clinical manifestation and bone marrow features of AML subtype M5b associated with t(8;16)(p11;p13).
  • Therefore, we believe that the t(8;18;16) is a new variant of t(8;16) related to AML M4/M5.
  • [MeSH-major] Chromosomes, Human, Pair 18. Chromosomes, Human, Pair 8. Genetic Variation. Leukemia, Monocytic, Acute / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Monoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16490600.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


20. Ondrousková E, Povolná K, Vána P, Benes P, Konecná H, Zdráhal Z, Smarda J: A proteomic analysis of protein variations during differentiation of v-myb-transformed monoblasts. Leuk Res; 2007 Feb;31(2):221-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • v-myb oncogene of avian myeloblastosis virus (AMV) transforms myelomonocytic cells in vitro and induces acute monoblastic leukemia in vivo.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16930693.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydroxamic Acids; 0 / Oncogene Proteins v-myb; 0 / Phorbol Esters; 0 / Proteins; 3X2S926L3Z / trichostatin A
  •  go-up   go-down


21. Heras M, Saiz A, Sánchez R, Fernandez-Reyes MJ, Mampaso F, Queizán J, Molina A, Vázquez L, Alvarez-Ude F: Nephrotic syndrome resulting from focal segmental glomerulosclerosis in a peripheral blood stem cell transplant patient. J Nephrol; 2007 Jul-Aug;20(4):495-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe the case of a male patient who was diagnosed with acute monoblastic leukemia and received a peripheral stem cell transplantation (PSCT) with peripheral blood hematopoietic progenitors.
  • Because he was in clinical remission with no evidence of chronic graft-versus-host disease (GVHD), immunosuppression was withdrawn, and he developed nephrotic syndrome (NS) months later.
  • [MeSH-major] Glomerulosclerosis, Focal Segmental / complications. Graft vs Host Disease / complications. Hematopoietic Stem Cell Transplantation. Nephrotic Syndrome / diagnosis
  • [MeSH-minor] Adult. Humans. Immunosuppression. Leukemia, Monocytic, Acute / therapy. Male

  • Genetic Alliance. consumer health - Focal Segmental Glomerulosclerosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17879218.001).
  • [ISSN] 1121-8428
  • [Journal-full-title] Journal of nephrology
  • [ISO-abbreviation] J. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


22. Lee GY, Christina S, Tien SL, Ghafar AB, Hwang W, Lim LC, Lim TH: Acute promyelocytic leukemia with PML-RARA fusion on i(17q) and therapy-related acute myeloid leukemia. Cancer Genet Cytogenet; 2005 Jun;159(2):129-36
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute promyelocytic leukemia with PML-RARA fusion on i(17q) and therapy-related acute myeloid leukemia.
  • We describe a patient with acute promyelocytic leukemia (APL) and the karyotype 46,XX,i(17)(q10) with PML-RARA fusion gene detected by fluorescence in situ hybridization (FISH) and nested reverse transcriptase-polymerase chain reaction (RT-PCR).
  • FISH using dual-color translocation probes for PML (promyelocytic leukemia) and RARA (retinoic acid receptor-alpha) showed fusion signal for PML-RARA on both arms of i(17q).
  • Bone marrow examination suggested an acute monoblastic leukemia (AML-M5a) including the karyotype 46,XX,t(8;16) (p11.2;p13.3),inv(11)(p15q22 approximately q23)[11]/47,idem,+i(8)(q10)[9].
  • The occurrence of therapy related acute leukemia after successful therapy for APL is an emerging problem.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Chromosomes, Human, Pair 17. Isochromosomes. Leukemia, Monocytic, Acute / chemically induced. Leukemia, Promyelocytic, Acute / genetics. Neoplasm Proteins / genetics. Oncogene Proteins, Fusion / genetics. Receptors, Retinoic Acid / genetics. Tretinoin / adverse effects

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15899384.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / Receptors, Retinoic Acid; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 0 / retinoic acid receptor alpha; 143220-95-5 / PML protein, human; 5688UTC01R / Tretinoin
  •  go-up   go-down


23. Ishii E, Oda M, Kinugawa N, Oda T, Takimoto T, Suzuki N, Kosaka Y, Ohara A, Ogawa A, Ishii M, Sakata N, Okamura T, Koike K, Kojima S, Horibe K, Mizutani S: Features and outcome of neonatal leukemia in Japan: experience of the Japan infant leukemia study group. Pediatr Blood Cancer; 2006 Sep;47(3):268-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Features and outcome of neonatal leukemia in Japan: experience of the Japan infant leukemia study group.
  • BACKGROUND: Neonatal leukemia characterized by early stem cell origin and extramedullary infiltration in the first 4 weeks of life is rare.
  • We analyzed the features and outcome of neonatal leukemia in Japan to establish an appropriate treatment strategy for this rare disorder.
  • PROCEDURE: Patients with infant leukemia registered and treated in the Japan Infant Leukemia Study between 1996 and 2001 were analyzed.
  • RESULTS: Among 162 infant leukemia patients, 11 exhibited neonatal leukemia; frequencies for all infant leukemias were 6.9% (8/116) for acute lymphoblastic leukemia (ALL) and 7.3% (3/41) for acute myeloid leukemia (AML).
  • Positive MLL gene rearrangement was observed in all eight patients with ALL; a single patient with AML displayed germline configuration.
  • Acute monoblastic leukemia was apparent in all three patients with AML (M5a in the FAB classification).
  • Most of the patients demonstrated hepatoplenomegaly and hyperleukocytosis at diagnosis.
  • Four patients (one with AML, and three with ALL) have survived following stem cell transplantation (SCT); however, growth impairment related to SCT was observed in these patients.
  • CONCLUSIONS: These results suggest an improvement attributable to treatment of neonatal leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation
  • [MeSH-minor] Acute Disease. Female. Histone-Lysine N-Methyltransferase. Humans. Infant. Infant, Newborn. Japan / epidemiology. Male. Myeloid-Lymphoid Leukemia Protein / genetics. Registries. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Blood Cancer. 2006 Sep;47(3):234-5 [16206196.001]
  • (PMID = 16333820.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


24. Douet-Guilbert N, Morel F, Le Bris MJ, Herry A, Morice P, Bourquard P, Banzakour S, Le Calvez G, Marion V, Berthou C, De Braekeleer M: Rearrangement of the MLL gene in acute myeloblastic leukemia: report of two rare translocations. Cancer Genet Cytogenet; 2005 Mar;157(2):169-74
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rearrangement of the MLL gene in acute myeloblastic leukemia: report of two rare translocations.
  • We report here 2 male adults in whom a diagnosis of acute myelomonoblastic leukemia (FAB M4) and acute monoblastic leukemia (FAB M5) was made.
  • Fourteen and 24 patients, including ours, with acute myeloblastic leukemia associated with a t(1;11)(p32;q23) and a t(11;17)(q23;q21), respectively have been reported in the literature.
  • Several patients with the latter translocation have also been identified to have acute lymphoblastic leukemia (ALL).
  • Although both translocations are preferentially associated with monocytic differentiation, the t(11;17)(q23;q21) is more common in adults and has been reported in many patients with ALL, compared to the t(1;11)(p32;q23).
  • [MeSH-major] Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 17. DNA-Binding Proteins / genetics. Leukemia, Myeloid, Acute / genetics. Proto-Oncogenes / genetics. Transcription Factors / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Histone-Lysine N-Methyltransferase. Humans. Karyotyping. Male. Middle Aged. Myeloid-Lymphoid Leukemia Protein

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721641.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / Transcription Factors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


25. Alonso CN, Longo PL, Gallego MS, Medina A, Felice MS: A novel AF9 breakpoint in MLL-AF9-positive acute monoblastic leukemia. Pediatr Blood Cancer; 2008 Apr;50(4):869-71
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel AF9 breakpoint in MLL-AF9-positive acute monoblastic leukemia.
  • MLL-AF9 is the most frequent MLL rearrangement in childhood acute myeloid leukemia (AML) and it may be also found in acute lymphoblastic leukemia (ALL) of patients younger than 1-year-old (infants).
  • We report a novel AF9 breakpoint site, located between previously reported sites A and B, detected in an infant who was diagnosed with AML-FAB M5.
  • The precise characterization of the MLL-AF9 transcript is important to carry out the minimal residual disease analysis during the follow-up of the patients.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Oncogene Proteins, Fusion / genetics

  • Genetic Alliance. consumer health - Acute Monoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18000862.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL-AF9 fusion protein, human; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  •  go-up   go-down


26. Saito B, Nakamaki T, Nakashima H, Usui T, Hattori N, Kawakami K, Tomoyasu S: Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia. Am J Hematol; 2007 Apr;82(4):304-6
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia.
  • Acute monoblastic leukemia was diagnosed.
  • No infiltration of leukemia cells was seen.
  • These details suggest not only that direct cerebral neurotoxicity of cytarabine but also that some type of allergic response may have been involved in the development of RPLS.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Brain Diseases / chemically induced. Cytarabine / adverse effects. Leukemia, Monocytic, Acute / drug therapy. Neurotoxicity Syndromes / etiology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16947320.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  •  go-up   go-down


27. Malbora B, Senel E, Avci Z, Ozbek N: Purpuric nodules and macules on the scalp of an 18-month-old boy. Skinmed; 2010 Sep-Oct;8(5):305-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An 18-month-old boy was consulted to a pediatric clinic with a 5-month history of purpuric macules and nodules on the scalp.
  • Bone marrow aspirate results showed 68.4% blast cells and a biopsy specimen confirmed the diagnosis of acute myeloid leukemia, with flow cytometry findings positive for acute monoblastic leukemia (AML) French-American-British (FAB)-M5 phenotype.
  • We initiated induction chemotherapy for AML (AML-M5) according to the AML Berlin-Frankfurt-Munster 2004 protocol.
  • ' Complete resolution of the leukemia cutis lesions was attained with chemotherapy at the end of the first month of treatment.
  • [MeSH-major] Leukemia, Monocytic, Acute / pathology. Scalp Dermatoses / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Dandruff, Cradle Cap, and Other Scalp Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Skinmed. 2011 Jan-Feb;9(1):66
  • (PMID = 21137646.001).
  • [ISSN] 1540-9740
  • [Journal-full-title] Skinmed
  • [ISO-abbreviation] Skinmed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD68 antigen, human; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


28. Pasmant E, Sabbagh A, Hanna N, Masliah-Planchon J, Jolly E, Goussard P, Ballerini P, Cartault F, Barbarot S, Landman-Parker J, Soufir N, Parfait B, Vidaud M, Wolkenstein P, Vidaud D, France RN: SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype. J Med Genet; 2009 Jul;46(7):425-30
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype.
  • OBJECTIVE: Germline loss-of-function mutations in the SPRED1 gene have recently been identified in patients fulfilling the National Institutes of Health (NIH) diagnostic criteria for neurofibromatosis type 1 (NF1) but with no NF1 (neurofibromin 1) mutation found, suggesting a neurofibromatosis type 1-like syndrome.
  • METHODS: 61 index cases with NF1 clinical diagnosis but no identifiable NF1 mutation were screened for SPRED1 mutation.
  • RESULTS: We describe one known SPRED1 mutation (c.190C>T leading to p.Arg64Stop) and four novel mutations (c.637C>T leading to p.Gln213Stop, c.2T>C leading to p.Met1Thr, c.46C>T leading to p.Arg16Stop, and c.1048_1060del leading to p.Gly350fs) in five French families.
  • It is noteworthy that one patient with the p.Arg16Stop mutation developed a monoblastic acute leukaemia.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. DNA Mutational Analysis. Female. Gene Dosage. Genetic Predisposition to Disease. Humans. Male. Middle Aged. Pedigree


29. Liu LB, Li L, Zou P: Comparison of cytogenetics and clinical manifestations between M5a and M5b of acute monocytic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug;14(4):654-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of cytogenetics and clinical manifestations between M5a and M5b of acute monocytic leukemia.
  • To compare the cytogenetic difference between M5a and M5b of acute monocytic leukemia and to study the correlation between karyotypes and clinical manifestations, a total of 58 cases of de novo adult AML M5 have been investigated.
  • The frequency of normal karyotype in patients with M5b was significantly higher than that in patients with M5a (P = 0.0001).
  • The 11q23 aberrations and trisomy 8 were more common in patients with M5a in comparison with patients with M5b (P < 0.01).
  • The patients with AML M5 with aberrant karyotype had a higher incidence of hyperleukocytosis, extramedullary central nerve system infiltration, lower complete remission (CR) rate and shorter overall survival.
  • It is concluded that acute monocytic leukemia is a series of heterogeneous diseases, a distinctive cytogenetic features can be observed between patients with AML M5a and M5b, these results will provide insights into the classification and pathogenesis mechanism of AML M5 at molecular level.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16928293.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  •  go-up   go-down


30. Hattori T, Amano H, Nagai Y, Ishikawa O: Leukemia cutis in a patient with acute monocytic leukemia presenting as unique facial erythema. J Dermatol; 2008 Oct;35(10):671-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia cutis in a patient with acute monocytic leukemia presenting as unique facial erythema.
  • She had been diagnosed as having acute monocytic leukemia (French-American-British classification, M5b) based on the histological findings of bone marrow.
  • Specific cutaneous lesions could occur in acute monocytic leukemia more frequently than in other types of leukemia, but rarely show symmetrical edematous erythema limited to the face.
  • [MeSH-major] Erythema / diagnosis. Facial Dermatoses / diagnosis. Leukemia, Monocytic, Acute / pathology. Leukemic Infiltration / diagnosis. Skin / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19017048.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


31. Chen S, Xue Y, Zhang X, Wu Y, Pan J, Wang Y, Ceng J: A new human acute monocytic leukemia cell line SHI-1 with t(6;11)(q27;q23), p53 gene alterations and high tumorigenicity in nude mice. Haematologica; 2005 Jun;90(6):766-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new human acute monocytic leukemia cell line SHI-1 with t(6;11)(q27;q23), p53 gene alterations and high tumorigenicity in nude mice.
  • BACKGROUND AND OBJECTIVES: Human leukemia cell lines are of great value in leukemia research.
  • Thus far 36 leukemia cell lines carrying the 11q23 translocation and MLL rearrangements, including two cell lines with t(6;11)(q27;q23) and an MLL-AF6 fusion gene have been described.
  • We have established a new monocytic cell line with t(6;11), designated SHI-1, and herein describe its biological characteristics.
  • DESIGN AND METHODS: Mononuclear cells isolated from the bone marrow of a patient with acute monocytic leukemia (AML-M5b) at relapse were inoculated and passaged by liquid culture.
  • The morphology and immunoprofile of the cells show typical features of monocytic lineage.
  • Karyotypic analysis demonstrated a t(6;11)(q27;q23) translocation accompanied by a deletion of 17p, which are the same abnormalities as were seen in the leukemia cells of this patient in relapse.
  • The MLL-AF6 fusion transcript and the loss of one p53 allele were proven by chromosome painting, FISH and RT-PCR analysis in both SHI-1 cells and the primary leukemia cells.
  • A point mutation of ATC-->ACC at codon 195 of exon 6 in another p53 allele was found by direct sequencing of DNA in SHI-1 cells as well as in the primary leukemia cells.
  • INTERPRETATION AND CONCLUSIONS: SHI-1 is a new monocytic leukemia cell line with the t(6;11) translocation, p53 gene alterations, and high tumorigenicity in nude mice.
  • [MeSH-major] Cell Line, Tumor. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 6. Genes, p53. Leukemia, Monocytic, Acute / genetics. Translocation, Genetic

  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951289.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


32. Demirer S, Ozdemir H, Sencan M, Marakoglu I: Gingival hyperplasia as an early diagnostic oral manifestation in acute monocytic leukemia: a case report. Eur J Dent; 2007 Apr;1(2):111-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gingival hyperplasia as an early diagnostic oral manifestation in acute monocytic leukemia: a case report.
  • Acute Myeloblastic Leukemia (AML) is a malignant disease of bone marrow.
  • Due to its high morbidity rate, early diagnosis and appropriate medical therapy is essential.
  • Rapidly forming gingival hyperplasia is usually the first sign of this disease.
  • A medical consultation was asked from hematology clinics and after a detailed medical examination Acute Monocytic Leukemia (FAB M5) was rendered.
  • The patient responded well to chemotherapeutic induction regimen and after two months of medical therapy disease remised and gingival hyperplasia regressed.
  • This case report shows that the gingival hyperplasia may represent an initial manifestation of an underlying systemic disease.
  • Also, early medical therapy in acute monocytic leukemia may resolve the gingival hyperplasia that companies the disease progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aust Dent J. 1996 Aug;41(4):235-7 [8870276.001]
  • [Cites] J Nihon Univ Sch Dent. 1997 Jun;39(2):67-70 [9293702.001]
  • [Cites] J Am Dent Assoc. 1988 Dec;117(7):835-7 [3204244.001]
  • [Cites] J Periodontol. 1984 Oct;55(10):585-8 [6387081.001]
  • [Cites] J Am Dent Assoc. 1986 Dec;113(6):899-900 [3466936.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1986 May;61(5):466-70 [3459123.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1983 Jun;55(6):572-9 [6576290.001]
  • [Cites] Int J Oral Surg. 1978 Apr;7(2):119-22 [98458.001]
  • [Cites] J Periodontol. 2002 Jun;73(6):664-8 [12083541.001]
  • [Cites] J Periodontol. 2000 May;71(5 Suppl):876-9 [10875698.001]
  • [Cites] Ann Periodontol. 1999 Dec;4(1):54-64 [10863375.001]
  • [Cites] Mt Sinai J Med. 1998 Oct-Nov;65(5-6):309-15 [9844357.001]
  • [Cites] J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):491-9 [15761428.001]
  • [Cites] J Can Dent Assoc. 2000 Feb;66(2):78-9 [10730004.001]
  • [Cites] J Periodontol. 1988 Dec;59(12):852-5 [3225733.001]
  • (PMID = 19212486.001).
  • [ISSN] 1305-7456
  • [Journal-full-title] European journal of dentistry
  • [ISO-abbreviation] Eur J Dent
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Other-IDs] NLM/ PMC2609944
  • [Keywords] NOTNLM ; Acute monocytic leukemia / Gingival hyperplasia
  •  go-up   go-down


33. Al-Tawfiq JA, Al-Khatti AA: Spontaneous remission of acute monocytic leukemia after infection with Clostridium septicum. Int J Lab Hematol; 2007 Oct;29(5):386-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous remission of acute monocytic leukemia after infection with Clostridium septicum.
  • Spontaneous remissions of acute myeloid leukemia (AML) have been reported in association with infection.
  • Here, we report a case of spontaneous remission of AML in a 47-year-old Saudi Arabian male patient who presented with a few weeks history of recurrent abdominal pain, vomiting and fever.
  • He was diagnosed with acute monocytic leukemia (AML, FAB M5b) and a perforated bowel.
  • Similarly, previous reports of spontaneous remission of AML were short lived and were followed by relapse and progression.
  • [MeSH-major] Clostridium Infections / complications. Clostridium septicum / pathogenicity. Intestinal Perforation / complications. Leukemia, Monocytic, Acute / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17824921.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


34. Lee WJ, Ou HC, Hsu WC, Chou MM, Tseng JJ, Hsu SL, Tsai KL, Sheu WH: Ellagic acid inhibits oxidized LDL-mediated LOX-1 expression, ROS generation, and inflammation in human endothelial cells. J Vasc Surg; 2010 Nov;52(5):1290-300
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, oxLDL induced the phosphorylation of p38 mitogen-activated protein kinase, activated the NF-κB-mediated inflammatory signaling molecules interleukin-(IL) 6 and IL-8 and the adhesion molecules intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin, and stimulated the adherence of THP-1 (a human acute monocytic leukemia cell line) to HUVECs.
  • [MeSH-minor] Cell Adhesion Molecules / metabolism. Cells, Cultured. Dose-Response Relationship, Drug. Down-Regulation. Enzyme Inhibitors / pharmacology. Humans. Inflammation Mediators / metabolism. Interleukin-6 / metabolism. Interleukin-8 / metabolism. NADPH Oxidase / antagonists & inhibitors. NADPH Oxidase / metabolism. NF-kappa B / metabolism. Nitric Oxide / metabolism. Nitric Oxide Synthase Type II / metabolism. Nitric Oxide Synthase Type III / metabolism. Onium Compounds / pharmacology. Phosphorylation. Signal Transduction / drug effects. Superoxides / metabolism. p38 Mitogen-Activated Protein Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. ELLAGIC ACID .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.
  • [CommentIn] J Vasc Surg. 2010 Nov;52(5):1300 [21050989.001]
  • (PMID = 20692795.001).
  • [ISSN] 1097-6809
  • [Journal-full-title] Journal of vascular surgery
  • [ISO-abbreviation] J. Vasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antioxidants; 0 / Cell Adhesion Molecules; 0 / Enzyme Inhibitors; 0 / IL6 protein, human; 0 / IL8 protein, human; 0 / Inflammation Mediators; 0 / Interleukin-6; 0 / Interleukin-8; 0 / Lipoproteins, LDL; 0 / NF-kappa B; 0 / OLR1 protein, human; 0 / Onium Compounds; 0 / Reactive Oxygen Species; 0 / Scavenger Receptors, Class E; 0 / oxidized low density lipoprotein; 11062-77-4 / Superoxides; 19YRN3ZS9P / Ellagic Acid; 31C4KY9ESH / Nitric Oxide; 6HJ411TU98 / diphenyleneiodonium; EC 1.14.13.39 / NOS2 protein, human; EC 1.14.13.39 / NOS3 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.13.39 / Nitric Oxide Synthase Type III; EC 1.6.3.1 / NADPH Oxidase; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


35. Subramanian M, Shaha C: Oestrogen modulates human macrophage apoptosis via differential signalling through oestrogen receptor-alpha and beta. J Cell Mol Med; 2009 Aug;13(8B):2317-29
Hazardous Substances Data Bank. ESTRADIOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An earlier study from this laboratory demonstrated 17beta-oestradiol (E2) induced apoptosis in macrophages derived from human peripheral blood monocytes and THP-1 acute monocytic leukaemia cell line when Bcl-2 was down-regulated; however, the involvement of E2 receptor subtypes in the modulation of death pathways in these cells remain unknown.
  • Using macrophages derived from THP-1 human acute monocytic leukaemia cells as a model, we demonstrate that plasma membrane associated oestrogen receptor (ER) -alpha participate in E2 induced Bcl-2 increase, through activation of the mitogen activated protein kinase (MAPK) pathway whereas cytosolic ER-beta transmits signals for the pro-apoptotic event of Bax translocation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20141615.001).
  • [ISSN] 1582-4934
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 4TI98Z838E / Estradiol
  •  go-up   go-down


36. Kusari S, Zühlke S, Kosuth J, Cellárová E, Spiteller M: Light-independent metabolomics of endophytic Thielavia subthermophila provides insight into microbial hypericin biosynthesis. J Nat Prod; 2009 Oct;72(10):1825-35
SILVA. SILVA LSU Database .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The endophytic metabolites exhibited photodynamic cytotoxicity against the human acute monocytic leukemia cell line (THP-1), at 92.7 vs 4.9%, and 91.1 vs 1.0% viability by resazurin and ATPlite assays, in light and in the dark, respectively.

  • Hazardous Substances Data Bank. PERYLENE .
  • Hazardous Substances Data Bank. EMODIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19746917.001).
  • [ISSN] 1520-6025
  • [Journal-full-title] Journal of natural products
  • [ISO-abbreviation] J. Nat. Prod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5QD5427UN7 / Perylene; 7V2F1075HD / hypericin; KA46RNI6HN / Emodin
  •  go-up   go-down


37. Wu JY, Chung KT, Liu YW, Lu FJ, Tsai RS, Chen CH, Chen CH: Synthesis and biological evaluation of novel C(6) modified baicalein derivatives as antioxidative agents. J Agric Food Chem; 2008 Apr 23;56(8):2838-45
Hazardous Substances Data Bank. CUMENE HYDROPEROXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Flow cytometrical method was employed to measure the intracellular antioxidative activity and GSH depletion capacity of these derivatives in human acute monocytic leukemia cell line (THP-1).
  • [MeSH-minor] Alkylation. Benzene Derivatives / pharmacology. Benzothiazoles. Cell Line, Tumor. Free Radical Scavengers / chemistry. Glutathione / metabolism. Humans. Leukemia, Monocytic, Acute. Sulfonic Acids. Terpenes / chemistry

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18348528.001).
  • [ISSN] 0021-8561
  • [Journal-full-title] Journal of agricultural and food chemistry
  • [ISO-abbreviation] J. Agric. Food Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Benzene Derivatives; 0 / Benzothiazoles; 0 / Flavanones; 0 / Free Radical Scavengers; 0 / Sulfonic Acids; 0 / Terpenes; 28752-68-3 / 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid; 49QAH60606 / baicalein; GAN16C9B8O / Glutathione; PG7JD54X4I / cumene hydroperoxide
  •  go-up   go-down


38. Chen SN, Xue YQ, Zhang XG, Wu YF, Pan JL, Wang Y, Cen JN: [Establishment and characterization of a human acute monocytic leukemic cell line, SHI-1, carrying t(6;11)(q27;23) and p53 gene alteration]. Zhonghua Xue Ye Xue Za Zhi; 2005 Feb;26(2):94-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Establishment and characterization of a human acute monocytic leukemic cell line, SHI-1, carrying t(6;11)(q27;23) and p53 gene alteration].
  • OBJECTIVE: To establish a novel human monocytic leukemic cell line and characterize its biological features.
  • METHODS: Mononuclear cells isolated from the bone marrow of an acute monocytic leukemia (AML-M(5b)) patient at relapse were inoculated in a liquid culture system.
  • And the biologic features of the established cell line SHI-1 were characterized by morphology, cytochemical staining, flow cytometry, karyotypic analysis, polymerase chain reaction (PCR), reverse transcriptase PCR (RT-PCR), fluorescence in situ hybridization (FISH), tumorigenicity in nude mice, quantitative fluorescent polymerase chain reaction, broth medium culture, short tandem repeating sequences-PCR (STR-PCR), multiplex-FISH (M-FISH), and (3)H-thymidine incorporation assay.
  • RESULTS: A human acute monocytic leukemia cell line, SHI-1, was established and has proliferated continuously in vitro for over one year.
  • The cell line presented typical morphology and immuno-profile of monocytic lineage with the original t(6;11)(q27;q23) and del(17)(p11) abnormalities.
  • CONCLUSIONS: SHI-1 is a novel acute monocytic leukemia-derived cell line carrying t(6;11)(q27;q23) and p53 gene alteration and having high tumorigenicity in nude mice.
  • It provides a new useful tool for leukemia research.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 6 / genetics. Leukemia, Monocytic, Acute / genetics. Translocation, Genetic. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Animals. Bone Marrow Cells / metabolism. Bone Marrow Cells / pathology. Cell Line, Tumor. Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Leukemia, Experimental / blood. Leukemia, Experimental / genetics. Leukemia, Experimental / pathology. Male. Mice. Mice, Nude. Transplantation, Heterologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921626.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


39. Fatahzadeh M, Krakow AM: Manifestation of acute monocytic leukemia in the oral cavity: a case report. Spec Care Dentist; 2008 Sep-Oct;28(5):190-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Manifestation of acute monocytic leukemia in the oral cavity: a case report.
  • Within a week he developed signs and symptoms of systemic disease and upon further investigation, he was diagnosed with acute monocytic leukemia to which he succumbed within 72 hours.
  • The implications of gingival bleeding are discussed, and the necessity to consider systemic disease in the differential diagnosis is emphasized.
  • [MeSH-major] Gingival Hemorrhage / etiology. Leukemia, Monocytic, Acute / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18782195.001).
  • [ISSN] 0275-1879
  • [Journal-full-title] Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry
  • [ISO-abbreviation] Spec Care Dentist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Sindt A, Deau B, Brahim W, Staal A, Visanica S, Villarese P, Rault JP, Macintyre E, Delabesse E: Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9. Genes Chromosomes Cancer; 2006 Jun;45(6):575-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9.
  • The t(9;22)(q34;q11) translocation occurs in chronic myeloid leukemia (CML) and adult B-cell acute lymphoblastic leukemia (ALL), leading to fusion of BCR to ABL1 and constitutive activation of ABL1 tyrosine kinase activity.
  • We describe here the first case of t(9;22)(q34;q11) associated with t(10;11)(p13;q14) in acute monocytic leukemia.
  • The recurrent t(10;11)(p13;q14) translocation, usually found in acute myeloid leukemia (AML) and T-ALL, merges PICALM to MLLT10.
  • RT-PCR enabled identification of PICALM-MLLT10 and BCR-ABL1 e1-a2 fusion transcripts; in the context of chronic and acute myeloid leukemia, the latter usually has a monocytic presentation.
  • We also identified overexpression of HOXA9, a gene essential to myeloid differentiation that is expressed in PICALM-MLLT10 and MLL-rearranged acute leukemias.
  • This case fits with and extends a recently proposed multistage AML model in which constitutive activation of tyrosine kinases by mutations (BCR-ABL1) are associated with deregulation of transcription factors central to myeloid differentiation (HOXA9 secondary to PICALM-MLLT10).
  • [MeSH-major] Fusion Proteins, bcr-abl / metabolism. Gene Expression Regulation, Neoplastic. Homeodomain Proteins / metabolism. Leukemia, Monocytic, Acute / genetics. Oncogene Proteins, Fusion / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16518848.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / MLLT10 protein, human; 0 / Monomeric Clathrin Assembly Proteins; 0 / Oncogene Proteins, Fusion; 0 / PICALM protein, human; 0 / PICALM-MLLT10 fusion protein, human; 0 / Transcription Factors; 0 / homeobox protein HOXA9; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


41. Chen G, Zhang W, Cao X, Li F, Liu X, Yao L: Serological identification of immunogenic antigens in acute monocytic leukemia. Leuk Res; 2005 May;29(5):503-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serological identification of immunogenic antigens in acute monocytic leukemia.
  • In order to improve disease-free survival and potentially a cure, it is necessary to identify more potent leukemia antigen.
  • Here, we defined the acute monocytic leukemia-associated antigen (LAA) recognized by the humoral immune system for the first time.
  • We have applied the method of serologic analysis of recombinant cDNA expression library (SEREX) on acute monocytic leukemia (FAB M5), followed by DNA sequencing and analyzing of positive clones.
  • Then, the reactivity of normal and other leukemia sera with positive clones were performed.
  • Thirty-five distinct novel antigens reactive with autologous IgG were identified by SEREX analysis on an acute monocytic leukemia patient and were characterized according to cDNA sequence and the reactivity with allogeneic sera.
  • Twenty of the 35 antigens identified in this study were recognized by IgG antibodies in normal sera, and the remaining 15 were recognized exclusively by sera from allogeneic leukemia patients but not by normal donor sera, suggested that the immune response to these 15 antigens are leukemia related.
  • The 15 immunogenic antigens detected by immune responses in the autologous host facilitate the identification of epitopes recognized by antigen-specific cytotoxic T lymphocytes (CTL) and are potential candidates for diagnosis and immunotherapy in acute myeloid leukemia (AML).
  • [MeSH-major] Antibodies, Neoplasm / immunology. Antigens, Neoplasm / immunology. Immunoglobulin G / immunology. Leukemia, Monocytic, Acute / immunology. T-Lymphocytes, Cytotoxic / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755502.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Immunoglobulin G
  •  go-up   go-down


42. Yamamoto K, Okamura A, Wakahashi K, Katayama Y, Shimoyama M, Matsui T: A novel unbalanced whole-arm translocation der(3;10)(q10;q10) in acute monocytic leukemia. Cancer Genet Cytogenet; 2010 Jun;199(2):134-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel unbalanced whole-arm translocation der(3;10)(q10;q10) in acute monocytic leukemia.
  • We describe here a novel unbalanced whole-arm translocation der(3;10)(q10;q10) in a 58-year-old man with acute monocytic leukemia.
  • These monocytic cells were positive for myeloperoxidase and alpha-naphthyl butyrate esterase staining.
  • Spectral karyotyping confirmed der(3;10)(q10;q10) as a sole structural abnormality.
  • The +3,der(3;10)(q10;q10) is thought to play a crucial role in the pathogenesis of acute monocytic leukemia because of the gain of 3q or the loss of 10p.
  • [MeSH-major] Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 3 / genetics. Leukemia, Monocytic, Acute / genetics. Translocation, Genetic / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20471517.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. McGrattan P, Logan A, Humphreys M, Bowers M: Jumping translocation in acute monocytic leukemia (M5b) with alternative breakpoint sites in the long arm of donor chromosome 3. Med Oncol; 2010 Sep;27(3):667-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Jumping translocation in acute monocytic leukemia (M5b) with alternative breakpoint sites in the long arm of donor chromosome 3.
  • An 86-year-old man presented with acute hepatic failure, worsening thrombocytopenia, and anemia having been diagnosed and managed expectantly with cytogenetically normal RAEB-1.
  • After 20 months a diagnosis of disease transformation to acute monocytic leukemia (M5b) was made.
  • Conventional G-banded analysis of unstimulated peripheral blood cultures detected the proximal 3q1?2 JT clone involving recipient chromosome 10 several weeks after transformation to acute monocytic leukemia.
  • Palliative care was administered until his demise 2.2 months after disease transformation.
  • There have been fewer than 70 cases of acquired JTs reported in the literature, including one myeloproliferative neoplasm and five acute myeloid leukemias involving a single breakpoint site on donor chromosome 3.
  • [MeSH-major] Chromosome Breakpoints. Chromosomes, Human, Pair 3 / genetics. Leukemia, Monocytic, Acute / genetics. Translocation, Genetic
  • [MeSH-minor] Aged, 80 and over. Anemia, Refractory, with Excess of Blasts / genetics. Disease Progression. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Jan;14(1):119-22 [10637486.001]
  • [Cites] Leukemia. 2000 Sep;14(9):1630-3 [10995010.001]
  • [Cites] Haematologica. 2006 Dec;91(12):1596-604 [17145595.001]
  • [Cites] Pathol Biol (Paris). 2007 Feb;55(1):37-48 [16697122.001]
  • [Cites] Blood. 2007 Jan 15;109(2):431-48 [16960150.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1411-6 [9737690.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Apr 1;118(1):35-41 [10731588.001]
  • [Cites] Leukemia. 1995 Apr;9(4):634-9 [7723397.001]
  • [Cites] Leuk Res. 2004 Oct;28(10):1075-9 [15289020.001]
  • [Cites] Oncogene. 2007 Sep 6;26(41):5991-6001 [17369841.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Mar;109(2):144-9 [10087950.001]
  • [Cites] Br J Haematol. 2006 Jan;132(2):162-7 [16398650.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Jan 15;108(2):149-53 [9973944.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Aug;46(8):717-23 [17444494.001]
  • [Cites] Cancer Genet Cytogenet. 1988 Jul 1;33(1):29-33 [3164238.001]
  • [Cites] Cancer Genet Cytogenet. 1991 Feb;51(2):189-94 [1993304.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2079-88 [9058730.001]
  • [Cites] Cytogenet Cell Genet. 1988;48(4):224-7 [3248378.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Apr;24(4):295-8 [10092126.001]
  • [Cites] Cancer Genet Cytogenet. 1993 Nov;71(1):22-6 [8275449.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Feb;109(1):40-4 [9973958.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1514-9 [9473214.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Oct 1;98(1):20-7 [9309114.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1732-41 [9473240.001]
  • (PMID = 19629764.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Chen YX, Wang WP, Zhang PY, Zhang WG, Liu J, Ma XR: [Expression of genes psma6 and slc25a4 in patients with acute monocytic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct;17(5):1168-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of genes psma6 and slc25a4 in patients with acute monocytic leukemia].
  • The aim of this study was to investigate the expression levels of genes psma6 and slc25a4 in bone marrow of patients with acute monocytic leukemia and their correlation with clinical features and prognosis.
  • The expression levels of genes psma6 and slc25a4 in AML-M5 leukemia cells, normal blood cells and non-leukemia cells were detected by real-time quantitative RT-PCR and compared each other.
  • The results showed that the expression levels of psma6 mRNA in AML-M5 leukemia cells was lower than that in non AML-M5 leukemia cells, non-leukemia cells and normal blood cells.
  • The expression level of psma6 in AML-M5 patients with complete remission was higher than that in AML-M5 patients without remission.
  • The expression level of P27K protein in AML-M5 and AL correlated to leukocyte count in peripheral blood and LDH content.
  • The overexpression of slc25a4 mRNA was found in AML-M5, but there was no significant difference in slc25a4 mRNA expression between the patients with complete remission and those without remission.
  • It is concluded that the expression level of psma6 is probably a new prognostic indicator of acute monocytic leukemia, slc25a4 may be a novel gene of antigen associated with acute monocytic leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19840444.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adenine Nucleotide Translocator 1; EC 3.4.25.1 / PSMA6 protein, human; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


45. Ji YY, Zhang WG, Chen YX, Zhao XM, He AL, Liu J, Wang JL, Wang FX, Zhang PY, Zhang WJ: [Efficiency of GHA priming therapy on patients with acute monocytic leukemia and its mechanism]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb;18(1):213-8
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficiency of GHA priming therapy on patients with acute monocytic leukemia and its mechanism].
  • The aim of this study was to explore the clinical efficiency and side effects of GHA-priming therapy on patients with acute monocytic leukemia, and to analyze its mechanism.
  • 37 patients with refractory, relapse, hypocellular acute monocytic leukemia and elderly patients with AML-M(5) were treated with GHA-priming therapy (G-CSF, homoharringtonine and low dosage of cytarabine).
  • It is concluded that the GHA priming therapy can be used to treat patients with refractory, relapse, senile and hypocellular acute monocytic leukemia with satisfied response rate and low hematological and non-hematological toxicities.
  • MLAA-34 is a novel anti-apoptotic factor of acute monocytic leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20137150.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Harringtonines; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6FG8041S5B / homoharringtonine
  •  go-up   go-down


46. Nagashima N, Kano R, Hirai A, Yamazaki J, Inoue C, Hisasue M, Moore PF, Hasegawa A: Acute monocytic leukaemia in a cat. Vet Rec; 2005 Sep 17;157(12):347-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute monocytic leukaemia in a cat.
  • A three-year-old cat with lymphadenopathy, non-regenerative anaemia and marked leucocytosis (171.3 x 10(9) white blood cells/l) was diagnosed with monocytic leukaemia and treated with a combination of anticancer drugs.
  • A number of mature and immature monocyte-like cells were detected in the peripheral blood and bone marrow; they proved to be monocytic cells by cytochemical examination and an analysis of their cell surface phenotype, indicating that the cat suffered from acute myeloid leukaemia, subclassified as monocytic leukaemia (M5).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cat Diseases / diagnosis. Leukemia, Monocytic, Acute / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16170003.001).
  • [ISSN] 0042-4900
  • [Journal-full-title] The Veterinary record
  • [ISO-abbreviation] Vet. Rec.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


47. Morerio C, Acquila M, Rapella A, Tassano E, Rosanda C, Panarello C: Inversion (11)(p15q22) with NUP98-DDX10 fusion gene in pediatric acute myeloid leukemia. Cancer Genet Cytogenet; 2006 Dec;171(2):122-5
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inversion (11)(p15q22) with NUP98-DDX10 fusion gene in pediatric acute myeloid leukemia.
  • The inv(11)(p15q22), a rare but recurrent chromosome abnormality that creates a NUP98-DDX10 fusion gene, is associated with de novo or secondary myeloid malignancies.
  • We report a case of acute monocytic leukemia presenting this rearrangement, studied using fluorescence in situ hybridization (FISH) and reverse transcriptase-PCR (RT-PCR).
  • [MeSH-major] Chromosome Inversion. Chromosomes, Human, Pair 11 / genetics. DEAD-box RNA Helicases / genetics. Gene Fusion. Leukemia, Myeloid, Acute / genetics. Nuclear Pore Complex Proteins / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17116492.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AB040537/ AB040538
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Pore Complex Proteins; 0 / Nup98 protein, human; EC 3.6.1.- / DDX10 protein, human; EC 3.6.4.13 / DEAD-box RNA Helicases
  • [Number-of-references] 12
  •  go-up   go-down


48. Ge Y, Elghetany MT: CD36: a multiligand molecule. Lab Hematol; 2005;11(1):31-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD36 is commonly expressed on blasts in acute monocytic leukemia, megakaryoblastic leukemia, and erythroleukemia.
  • [MeSH-minor] Antigens, CD / physiology. Blast Crisis / pathology. Ethnic Groups. Gene Expression Regulation / immunology. Humans. Leukemia / blood. Malaria / blood. Malaria / immunology. Neovascularization, Physiologic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790550.001).
  • [ISSN] 1080-2924
  • [Journal-full-title] Laboratory hematology : official publication of the International Society for Laboratory Hematology
  • [ISO-abbreviation] Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD36
  • [Number-of-references] 70
  •  go-up   go-down


49. Mu QT, Ouyang GF, Lou YR, Chen XP, Lu Y, Liang W, Zhang Y, Xu W: [Inducing-apoptosis effect of bortezomib on acute monocytic leukemia cell SHI-1 and its influence on expressions of Bcl2l12, Bcl-2 and Bax genes]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct;16(5):1016-20
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inducing-apoptosis effect of bortezomib on acute monocytic leukemia cell SHI-1 and its influence on expressions of Bcl2l12, Bcl-2 and Bax genes].
  • This study was aimed to explore the effect of bortezomib on proliferation and apoptosis of acute monocytic leukemic cells SHI-1 and the function of Bcl-2 gene family including Bcl2l12, Bcl-2 and Bax in its apoptosis.
  • Bortezomib could induce apoptosis of SHI-1 cells in time-dependent manner, increase expression of Annexin-V positive cells, decrease DeltaPsim of SHI-1 cells and result in DNA fragmentation and morphologic changes of apoptosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18928586.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BCL2L12 protein, human; 0 / Boronic Acids; 0 / Muscle Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Pyrazines; 0 / RNA, Messenger; 0 / bcl-2-Associated X Protein; 69G8BD63PP / Bortezomib
  •  go-up   go-down


50. Schmutz C, Cartwright A, Williams H, Haworth O, Williams JH, Filer A, Salmon M, Buckley CD, Middleton J: Monocytes/macrophages express chemokine receptor CCR9 in rheumatoid arthritis and CCL25 stimulates their differentiation. Arthritis Res Ther; 2010;12(4):R161
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumour necrosis factor alpha (TNFα) increased CCR9 expression on human acute monocytic leukemia cell line THP-1 monocytic cells.

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 2010 Jul;62(7):1921-32 [20506316.001]
  • [Cites] IDrugs. 2010 Jul;13(7):472-81 [20582872.001]
  • [Cites] Eur J Immunol. 2000 Jan;30(1):262-71 [10602049.001]
  • [Cites] J Immunol. 2000 Feb 1;164(3):1293-305 [10640743.001]
  • [Cites] Ann Rheum Dis. 2000 May;59(5):399-400 [10836959.001]
  • [Cites] J Exp Med. 2000 Sep 4;192(5):761-8 [10974041.001]
  • [Cites] J Immunol. 2000 Nov 1;165(9):5069-76 [11046037.001]
  • [Cites] Gastroenterology. 2001 Aug;121(2):246-54 [11487533.001]
  • [Cites] Arthritis Rheum. 2001 Dec;44(12):2750-60 [11762935.001]
  • [Cites] Arthritis Rheum. 2002 Oct;46(10):2578-86 [12384915.001]
  • [Cites] J Clin Invest. 2002 Oct;110(8):1113-21 [12393847.001]
  • [Cites] Microcirculation. 2003 Jun;10(3-4):313-23 [12851648.001]
  • [Cites] Ann Rheum Dis. 2003 Aug;62(8):715-21 [12860725.001]
  • [Cites] Ther Apher Dial. 2003 Feb;7(1):48-59 [12921115.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):963-9 [12963696.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6469-77 [14559839.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Mar;36(3):372-8 [14687914.001]
  • [Cites] Ann Rheum Dis. 1991 Oct;50(10):673-6 [1958087.001]
  • [Cites] Ann Rheum Dis. 1994 May;53(5):315-22 [8017985.001]
  • [Cites] J Rheumatol. 1994 May;21(5):830-5 [7520499.001]
  • [Cites] J Rheumatol. 1994 Sep;21(9):1608-14 [7799336.001]
  • [Cites] J Exp Med. 1995 May 1;181(5):1857-62 [7536797.001]
  • [Cites] Arthritis Rheum. 1996 Jan;39(1):115-24 [8546720.001]
  • [Cites] Immunity. 1997 Aug;7(2):291-301 [9285413.001]
  • [Cites] Drugs Aging. 1998 May;12(5):377-90 [9606615.001]
  • [Cites] Arthritis Rheum. 1998 Nov;41(11):2032-8 [9811059.001]
  • [Cites] J Immunol. 1999 May 15;162(10):5671-5 [10229797.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8743-50 [15623660.001]
  • [Cites] J Immunol. 2005 Feb 1;174(3):1693-700 [15661933.001]
  • [Cites] Arthritis Res Ther. 2005;7(2):R217-29 [15743468.001]
  • [Cites] Arthritis Rheum. 2005 Mar;52(3):710-21 [15751074.001]
  • [Cites] Ann Rheum Dis. 2005 Jun;64(6):834-8 [15576415.001]
  • [Cites] Arthritis Rheum. 2005 Aug;52(8):2331-42 [16052590.001]
  • [Cites] J Immunol. 2005 Aug 15;175(4):2579-88 [16081832.001]
  • [Cites] Rheumatology (Oxford). 2005 Sep;44(9):1140-4 [15927997.001]
  • [Cites] Curr Rheumatol Rep. 2005 Oct;7(5):382-8 [16174489.001]
  • [Cites] J Autoimmun. 2005;25 Suppl:26-8 [16260118.001]
  • [Cites] Cell Immunol. 2005 Jul-Aug;236(1-2):110-4 [16185674.001]
  • [Cites] J Immunol. 2006 Jan 1;176(1):75-84 [16365398.001]
  • [Cites] Arthritis Rheum. 2006 Mar;54(3):765-78 [16508941.001]
  • [Cites] Histol Histopathol. 2007 May;22(5):581-6 [17330813.001]
  • [Cites] Curr Opin Rheumatol. 2007 May;19(3):289-95 [17414958.001]
  • [Cites] Methods. 2007 Nov;43(3):207-17 [17920517.001]
  • [Cites] Annu Rev Pathol. 2006;1:297-329 [18039117.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2008;48:171-97 [17883327.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):1920-7 [18723831.001]
  • [Cites] Mol Cell Biochem. 2010 Feb;335(1-2):283-9 [19784811.001]
  • [Cites] Expert Opin Investig Drugs. 2010 Mar;19(3):345-55 [20113217.001]
  • [Cites] J Exp Med. 1999 Nov 1;190(9):1241-56 [10544196.001]
  • (PMID = 20738854.001).
  • [ISSN] 1478-6362
  • [Journal-full-title] Arthritis research & therapy
  • [ISO-abbreviation] Arthritis Res. Ther.
  • [Language] eng
  • [Grant] United Kingdom / Arthritis Research UK / / 16390; United Kingdom / Arthritis Research UK / / 18547; United Kingdom / Medical Research Council / / G9818340; United Kingdom / Arthritis Research UK / / 20088; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CC chemokine receptor 9; 0 / CCL25 protein, human; 0 / Chemokines, CC; 0 / Receptors, CCR; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ PMC2945064
  •  go-up   go-down


51. Sung TJ, Lee DH, Kim SK, Jun YH: Congenital acute myeloid leukemia with t(8;16) and t(17;19) double translocation: case presentation and literature review. J Korean Med Sci; 2010 Jun;25(6):945-9
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital acute myeloid leukemia with t(8;16) and t(17;19) double translocation: case presentation and literature review.
  • Congenital leukemia is uncommon and excluding transient myeloproliferation associated with Down syndrome, makes up approximately 1% of childhood leukemias.
  • Bone marrow morphology was consistent with acute myeloid leukemia (M5) and cytogenetic studies revealed t(8;16) and t(17;19) double translocation.
  • Although prognosis of congenital leukemia is known to be dismal, recent reports showed spontaneous remissions.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2000 May-Jun;22(3):252-5 [10864057.001]
  • [Cites] J Am Acad Dermatol. 2006 Feb;54(2 Suppl):S22-7 [16427986.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Nov;139(1):57-9 [12547160.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 May;25(5):348-61 [12759620.001]
  • [Cites] Pediatr Hematol Oncol. 2004 Mar;21(2):135-44 [15160512.001]
  • [Cites] Clin Lab Haematol. 1980;2(3):243-5 [6933032.001]
  • [Cites] Pediatrics. 1983 Feb;71(2):277-9 [6823435.001]
  • [Cites] Pediatrics. 1983 Dec;72(6):916-7 [6646941.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1985 Winter;7(4):346-51 [3866495.001]
  • [Cites] Blood. 1987 May;69(5):1289-93 [2952182.001]
  • [Cites] Cancer Genet Cytogenet. 1988 Feb;30(2):233-8 [2830011.001]
  • [Cites] Cancer Genet Cytogenet. 1988 Sep;34(2):277-80 [3165702.001]
  • [Cites] J Am Acad Dermatol. 1989 Aug;21(2 Pt 2):347-51 [2754068.001]
  • [Cites] Pediatr Dermatol. 1989 Dec;6(4):306-11 [2694129.001]
  • [Cites] Eur J Pediatr. 1991 Mar;150(5):323-4 [2044602.001]
  • [Cites] Blood. 1991 Aug 1;78(3):748-52 [1859887.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1928-30 [8448758.001]
  • [Cites] Arch Dermatol. 1993 Oct;129(10):1301-6 [8215495.001]
  • [Cites] Cancer Genet Cytogenet. 1995 May;81(1):38-41 [7773958.001]
  • [Cites] Cytometry. 1995 Jun 15;22(2):89-92 [7587753.001]
  • [Cites] Pediatr Hematol Oncol. 1996 Mar-Apr;13(2):151-7 [8721029.001]
  • [Cites] Pediatr Dermatol. 1996 Nov-Dec;13(6):472-6 [8987056.001]
  • [Cites] Br J Haematol. 1997 Mar;96(4):740-2 [9074415.001]
  • [Cites] J Pediatr. 1997 Aug;131(2):176-7 [9290598.001]
  • [Cites] J Pediatr. 1997 Aug;131(2):300-3 [9290620.001]
  • [Cites] J Pediatr Hematol Oncol. 1999 Mar-Apr;21(2):152-7 [10206463.001]
  • [Cites] Semin Perinatol. 1999 Aug;23(4):274-85 [10475541.001]
  • [Cites] Pediatr Dermatol. 2005 Jan-Feb;22(1):26-30 [15660893.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Nov;163(1):71-3 [16271959.001]
  • [Cites] Br J Haematol. 2000 Nov;111(2):641-3 [11122113.001]
  • (PMID = 20514319.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Korea (South)
  • [Number-of-references] 30
  • [Other-IDs] NLM/ PMC2877231
  • [Keywords] NOTNLM ; Drug Therapy / Leukemia / Leukemic Infiltration / Translocation, Genetic
  •  go-up   go-down


52. Li M, Liu ZH, Chen Q, Zhou WQ, Yu MW, Lü GX, Lü XL, Shen YN, Liu WD, Wu SX: Insoluble beta-glucan from the cell wall of Candida albicans induces immune responses of human THP-1 monocytes through Dectin-1. Chin Med J (Engl); 2009 Mar 5;122(5):496-501
Hazardous Substances Data Bank. HYDROGEN PEROXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has been demonstrated that Dectin-1 as the principal C-type lectin pattern-recognition receptor (PRR) can recognize fungal beta-glucan and induce immune responses.
  • In this study, we sought to clarify whether insoluble beta-glucan from the cell wall of C. albicans (CaIG) could induce immune responses in human THP-1 monocytes (a human acute monocytic leukemia cell line) and to determine the underlying mechanisms.
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Enzyme-Linked Immunosorbent Assay. Gene Expression / drug effects. Humans. Hydrogen Peroxide / metabolism. Interleukin-8 / genetics. Interleukin-8 / metabolism. Lectins, C-Type. Reverse Transcriptase Polymerase Chain Reaction. Toll-Like Receptor 2 / genetics. Tumor Necrosis Factor-alpha / genetics. Tumor Necrosis Factor-alpha / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Chin Med J (Engl). 2009 Mar 5;122(5):483-5 [19323895.001]
  • (PMID = 19323897.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interleukin-8; 0 / Lectins, C-Type; 0 / Membrane Proteins; 0 / Nerve Tissue Proteins; 0 / Toll-Like Receptor 2; 0 / Tumor Necrosis Factor-alpha; 0 / beta-Glucans; 0 / dectin 1; BBX060AN9V / Hydrogen Peroxide
  •  go-up   go-down


53. Supronowicz P, Zhukauskas R, York-Ely A, Wicomb W, Thula T, Fleming L, Cobb RR: Immunologic analyses of bovine bone treated with a novel tissue sterilization process. Xenotransplantation; 2008 Nov-Dec;15(6):398-406

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TNF-alpha levels were significantly (P < 0.001) reduced compared with untreated controls when human acute monocytic leukemia cells were exposed to cortical or cancellous bone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19152668.001).
  • [ISSN] 1399-3089
  • [Journal-full-title] Xenotransplantation
  • [ISO-abbreviation] Xenotransplantation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens; 0 / Trisaccharides; 0 / Tumor Necrosis Factor-alpha; 0 / alpha-galactosyl epitope
  •  go-up   go-down


54. Inaba H, Fan Y, Pounds S, Geiger TL, Rubnitz JE, Ribeiro RC, Pui CH, Razzouk BI: Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. Cancer; 2008 Aug 1;113(3):522-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis.
  • BACKGROUND: Acute myeloid leukemia (AML) with hyperleukocytosis often is associated with early complications.
  • METHODS: The authors reviewed 579 patients with newly diagnosed pediatric AML who were treated at St. Jude Children's Research Hospital from 1968 to 2002 and carefully examined 106 patients with initial leukocyte counts > or = 100 x 10(9)/L and French-American-British (FAB) AML subtypes other than M3.
  • These patients with hyperleukocytosis were divided into 2 groups-'before' (early period; 70 patients) and 'after' (late period; 36 patients) the initiation of the AML-83 protocol-to address potential differences in supportive measures (including leukoreduction).
  • RESULTS: Forty-five patients (42.5%) had early complications that were associated strongly with M4 and M5 FAB subtypes and had higher initial leukocyte counts than the patients without complications.
  • CONCLUSIONS: With improved management, including supportive care, early mortality in patients with AML and hyperleukocytosis decreased remarkably in the more recent period.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / therapy. Leukocytosis / diagnosis. Leukocytosis / therapy

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society
  • (PMID = 18484648.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21765
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


55. Miyazawa M, Ito Y, Yoshida Y, Sakaguchi H, Suzuki H: Phenotypic alterations and cytokine production in THP-1 cells in response to allergens. Toxicol In Vitro; 2007 Apr;21(3):428-37
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have previously shown that THP-1 cells, human acute monocytic leukemia cell line, can discriminate between allergens and irritants by measuring expression of surface markers, CD86 and CD54, following chemical exposure.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SODIUM LAURYL SULFATE .
  • Hazardous Substances Data Bank. NICKEL, ELEMENTAL .
  • Hazardous Substances Data Bank. NICKEL SULFATE .
  • Hazardous Substances Data Bank. 1-CHLORO-2,4-DINITROBENZENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17118622.001).
  • [ISSN] 0887-2333
  • [Journal-full-title] Toxicology in vitro : an international journal published in association with BIBRA
  • [ISO-abbreviation] Toxicol In Vitro
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Allergens; 0 / Antigens, CD; 0 / Antigens, CD40; 0 / Biomarkers; 0 / CD83 antigen; 0 / Cytokines; 0 / Immunoglobulins; 0 / Irritants; 0 / Membrane Glycoproteins; 368GB5141J / Sodium Dodecyl Sulfate; 4FLT4T3WUN / nickel sulfate; 7OV03QG267 / Nickel; GE3IBT7BMN / Dinitrochlorobenzene
  •  go-up   go-down


56. Hubeek I, Peters GJ, Broekhuizen R, Zwaan CM, Kaaijk P, van Wering ES, Gibson BE, Creutzig U, Janka-Schaub GE, den Boer ML, Pieters R, Kaspers GJ: In vitro sensitivity and cross-resistance to deoxynucleoside analogs in childhood acute leukemia. Haematologica; 2006 Jan;91(1):17-23
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro sensitivity and cross-resistance to deoxynucleoside analogs in childhood acute leukemia.
  • BACKGROUND AND OBJECTIVES: Cytarabine (ara-C) is a key drug in the treatment of acute leukemia.
  • DESIGN AND METHODS: Using the MTT assay, we determined in vitro sensitivity and cross-resistance to deoxynucleoside analogs in 362 acute leukemia samples from untreated children and 32 normal bone marrow mononuclear cell samples.
  • RESULTS: Normal bone marrow samples were significantly more resistant to ara-C, cladribine and fludarabine than were acute myeloid leukemia (AML) samples and significantly more resistant to ara-C and fludarabine than were acute lymphoblastic leukemia (ALL) samples.
  • The only drug to which AML samples were more sensitive in vitro than ALL was cladribine.
  • AML FAB M5 was significantly more sensitive in vitro to ara-C and cladribine than FAB M1/2 or FAB M4.
  • A paired analysis of 60 AML and 99 ALL samples demonstrated significant cross-resistance between all four deoxynucleoside analogs.
  • Cross-resistance was also observed between ara-C and etoposide (Rp=0.54, p<0.0001), and ara-C and daunorubicin (Rp=0.48, p<0.0001) in AML.
  • INTERPRETATION AND CONCLUSIONS: Cladribine appears to be a useful drug in AML, particularly in FAB M5.
  • We observed cross-resistance between ara-C and other deoxynucleoside analogs, as well as between ara-C and drugs with different modes of action in childhood acute leukemia.
  • [MeSH-major] Drug Resistance, Multiple. Leukemia / drug therapy. Nucleosides / therapeutic use
  • [MeSH-minor] Acute Disease. Child. Cytarabine / therapeutic use. Drug Screening Assays, Antitumor. Humans

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434366.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Nucleosides; 04079A1RDZ / Cytarabine
  •  go-up   go-down


57. Adati N, Huang MC, Suzuki T, Suzuki H, Kojima T: High-resolution analysis of aberrant regions in autosomal chromosomes in human leukemia THP-1 cell line. BMC Res Notes; 2009;2:153
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution analysis of aberrant regions in autosomal chromosomes in human leukemia THP-1 cell line.
  • BACKGROUND: THP-1 is a human monocytic leukemia cell line derived from a patient with acute monocytic leukemia.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2009 May;41(5):553-62 [19377474.001]
  • [Cites] Leuk Res. 2000 Jan;24(1):39-46 [10634644.001]
  • [Cites] Nature. 2006 May 25;441(7092):475-82 [16598206.001]
  • [Cites] Leukemia. 2006 May;20(5):757-66 [16541141.001]
  • [Cites] J Comput Biol. 2006 Mar;13(2):215-28 [16597236.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4233-6 [10485463.001]
  • [Cites] Tohoku J Exp Med. 1998 Oct;186(2):99-119 [10223614.001]
  • [Cites] Hum Mol Genet. 1999 Feb;8(2):185-93 [9931326.001]
  • [Cites] Leukemia. 1994 Sep;8(9):1579-84 [8090034.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2431-5 [7919362.001]
  • [Cites] Experientia. 1991 Jan 15;47(1):22-31 [1999239.001]
  • [Cites] Semin Hematol. 1986 Jul;23(3):223-36 [3092357.001]
  • [Cites] Int J Cancer. 1980 Aug;26(2):171-6 [6970727.001]
  • [Cites] Cancer Res. 1982 Apr;42(4):1530-6 [6949641.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Apr;36(4):393-401 [12619163.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Oct 14;277(1):62-5 [11027640.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Dec;29(4):333-8 [11066077.001]
  • [Cites] Oncogene. 2008 Sep 18;27(41):5443-53 [18794879.001]
  • (PMID = 19635138.001).
  • [ISSN] 1756-0500
  • [Journal-full-title] BMC research notes
  • [ISO-abbreviation] BMC Res Notes
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2729307
  •  go-up   go-down


58. Ru YX, Mi YC, Liu JH, Wang HJ, Zhao SX, Cui W, Li CW, Li QH, Zhu XF, Xiao ZJ, Pang JX, Wang JX: Significance of transmission electron microscopy in subtyping of monocytic leukemia. Ultrastruct Pathol; 2009 Mar-Apr;33(2):67-75

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of transmission electron microscopy in subtyping of monocytic leukemia.
  • The objective of this paper is to produce an ultrastructural classification of acute monocytic leukemia (AML-M5) in relation to clinical behaviors.
  • The ultrastructural characteristics of blasts of the monocytic series were analyzed in 72 M5 patients by transmission electron microscopy (TEM), in terms of their content of typical monoblasts, atypical monoblasts, atypical promonocytes, and typical promonocytes in bone-marrow aspirates.
  • Four kinds of monocytic blasts were identified by cell size and shape, nuclear profile, nucleocytoplasmic ratio, heterochromatin content, nucleolus, granules, vesicles, and Golgi apparatus.
  • The data obtained permitted M5 patients to be divided into monoblast and promonocyte types.
  • Monoblast-type patients expressed weaker monocytic enzymograms and specific antigen staining for CD14 and CD64, compared with promonocyte-type patients.
  • Monoblast patients had higher CR than promonocyte patients.
  • [MeSH-major] Immunophenotyping / methods. Leukemia, Monocytic, Acute / classification. Microscopy, Electron, Transmission / methods. Monocyte-Macrophage Precursor Cells / ultrastructure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19274583.001).
  • [ISSN] 1521-0758
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


59. Shima T, Yoshimoto G, Nonami A, Yoshida S, Kamezaki K, Iwasaki H, Takenaka K, Miyamoto T, Harada N, Teshima T, Akashi K, Nagafuji K: Successful treatment of parainfluenza virus 3 pneumonia with oral ribavirin and methylprednisolone in a bone marrow transplant recipient. Int J Hematol; 2008 Oct;88(3):336-40
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 42-year-old woman diagnosed with acute myelogenous leukemia (FAB M5a) in first complete remission underwent allogeneic bone marrow transplantation from an HLA-matched unrelated donor in May 2006.
  • [MeSH-minor] Administration, Oral. Adult. Female. Humans. Leukemia, Myeloid, Acute / therapy. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 2000 Dec;31(6):1516-8 [11096028.001]
  • [Cites] J Heart Lung Transplant. 2005 Mar;24(3):343-6 [15737764.001]
  • [Cites] Biol Blood Marrow Transplant. 2001;7 Suppl:8S-10S [11777103.001]
  • [Cites] J Infect. 2004 Nov;49(4):262-73 [15474623.001]
  • [Cites] J Fam Pract. 1993 Aug;37(2):165-70 [8336098.001]
  • [Cites] Mayo Clin Proc. 1998 Feb;73(2):153-6 [9472999.001]
  • [Cites] Pharmacotherapy. 2003 Dec;23(12):1545-9 [14695034.001]
  • [Cites] Blood. 2001 Aug 1;98(3):573-8 [11468152.001]
  • [Cites] Transplantation. 2003 Jul 15;76(1):142-6 [12865800.001]
  • [Cites] Clin Microbiol Rev. 1994 Apr;7(2):265-75 [8055470.001]
  • [Cites] Respirology. 2006 Jul;11(4):437-41 [16771913.001]
  • [Cites] Biol Blood Marrow Transplant. 2001;7 Suppl:11S-15S [11777098.001]
  • [Cites] Clin Infect Dis. 2001 Feb 1;32(3):413-8 [11170949.001]
  • [Cites] Br J Haematol. 2002 Dec;119(4):1125-32 [12472597.001]
  • [Cites] Drugs. 2007;67(10):1411-27 [17600390.001]
  • [Cites] Respir Care. 2007 Jan;52(1):59-63 [18330040.001]
  • [Cites] Clin Pharmacol Ther. 1991 Oct;50(4):442-9 [1680594.001]
  • [Cites] Clin Pharmacol Ther. 1987 May;41(5):546-55 [3568539.001]
  • [Cites] Clin Infect Dis. 1996 Nov;23(5):1033-7 [8922798.001]
  • [Cites] Med Mal Infect. 2007 Sep;37(9):605-8 [17306485.001]
  • [Cites] Bone Marrow Transplant. 2000 Nov;26(10):1097-102 [11108309.001]
  • [Cites] N Engl J Med. 1990 Nov 22;323(21):1451-7 [2233917.001]
  • [Cites] Eur J Haematol. 2002 Jul;69(1):54-7 [12270063.001]
  • [Cites] Eur J Epidemiol. 1999 May;15(5):475-84 [10442474.001]
  • [Cites] Medicine (Baltimore). 2006 Sep;85(5):278-87 [16974212.001]
  • [Cites] Pediatrics. 2002 Jul;110(1 Pt 1):e9 [12093990.001]
  • [Cites] N Engl J Med. 1992 Apr 2;326(14):921-6 [1311800.001]
  • [Cites] Bone Marrow Transplant. 1997 May;19(9):905-8 [9156264.001]
  • [Cites] Antimicrob Agents Chemother. 1999 Oct;43(10):2451-6 [10508023.001]
  • (PMID = 18712461.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antiviral Agents; 49717AWG6K / Ribavirin; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


60. Scrideli CA, Baruffi MR, Squire JA, Ramos ES, Karaskova J, Heck B, Tone LG: Acute monocytic leukemia and multiple abnormalities in a child with duplication of 1q detected by GTG-banding and SKY. Leuk Res; 2005 Dec;29(12):1465-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute monocytic leukemia and multiple abnormalities in a child with duplication of 1q detected by GTG-banding and SKY.
  • We describe a case of partial trisomy 1q "syndrome" and acute monocytic leukemia.
  • The dismorphological features with the dup(1q) suggest a constitutional chromosome alteration and the first, in our knowledge, association of a trisomy 1q "syndrome" with AML.
  • [MeSH-major] Abnormalities, Multiple / genetics. Chromosomes, Human, Pair 1. Leukemia, Monocytic, Acute / genetics. Trisomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15964069.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


61. Gogălniceanu D, Trandafir V, Trandafir D, Popescu E: [Generalized gingival enlargement--early clinic manifestation in acute leukemia. Case report]. Rev Med Chir Soc Med Nat Iasi; 2010 Apr-Jun;114(2):576-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Generalized gingival enlargement--early clinic manifestation in acute leukemia. Case report].
  • [Transliterated title] Hiperplazia gingivală generalizată-- manifestare clinică precoce în leucemia acută. Prezentare de caz.
  • Leukemia is a hematological disorder arises from a hematopoietic stem cell characterized by a disordered differentiation and proliferation of neoplastic cells.
  • Rapidly forming generalized gingival hyperplasia is usually the first sign of this disease (especially in acute forms).
  • This case report describes a 54-year-old female who presented rapid gingival enlargement in only three weeks time, heralding the presence of acute monocytic leukemia (AML-FAB M5).
  • [MeSH-major] Gingival Hypertrophy / etiology. Leukemia, Monocytic, Acute / complications. Leukemia, Monocytic, Acute / diagnosis
  • [MeSH-minor] Early Diagnosis. Fatal Outcome. Female. Humans. Middle Aged. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701007.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


62. Osmond RI, Das S, Crouch MF: Development of cell-based assays for cytokine receptor signaling, using an AlphaScreen SureFire assay format. Anal Biochem; 2010 Aug;403(1-2):94-101
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With three different cell lines (human acute monocytic leukemia THP-1 cells, human erythroleukemic TF-1 cells, and human T lymphocytic Jurkat cells), we have optimized a rapid and homogeneous methodology for monitoring endogenous, receptor-mediated signaling via STAT 1, STAT 3, or STAT 5 phosphorylation, in response to several agonists.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20382104.001).
  • [ISSN] 1096-0309
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Cytokine; 0 / STAT Transcription Factors; 0 / STAT1 Transcription Factor; 0 / STAT3 Transcription Factor; 0 / STAT5 Transcription Factor
  •  go-up   go-down


63. Ning BT, Tang YM, Xu Y, Chen YF, Cao J: [Establishment of murine cell line transfected with human CD14 gene]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Apr;14(2):388-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was aimed to construct the CD14 eukaryotic expression vector, establish the transgeneic CD14 positive cell line in order to facilitate the establishment of a mouse model of antibody targeting therapy for human acute monocytic leukemia (AML-M(5)).
  • In conclusion, the murine cell line B16/CD14 fransfected with human CD14 gene has been established which can be used for the study of human AML-M(5) antibody targeting therapy with mouse model.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16638222.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD14; 0 / Antigens, Neoplasm
  •  go-up   go-down


64. Fujigaki H, Saito K, Lin F, Fujigaki S, Takahashi K, Martin BM, Chen CY, Masuda J, Kowalak J, Takikawa O, Seishima M, Markey SP: Nitration and inactivation of IDO by peroxynitrite. J Immunol; 2006 Jan 1;176(1):372-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study we found that IDO activity was inhibited by the peroxynitrite generator, 3-(4-morpholinyl)sydnonimine, in PMA-differentiated cytokine-induced THP-1 (acute monocytic leukemia) cells and IFN-gamma-stimulated PBMCs, whereas IDO protein expression was unaffected compared with that in untreated cells.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. L-TYROSINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16365430.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indoleamine-Pyrrole 2,3,-Dioxygenase; 14691-52-2 / Peroxynitrous Acid; 3604-79-3 / 3-nitrotyrosine; 42HK56048U / Tyrosine
  •  go-up   go-down


65. Hubeek I, Stam RW, Peters GJ, Broekhuizen R, Meijerink JP, van Wering ER, Gibson BE, Creutzig U, Zwaan CM, Cloos J, Kuik DJ, Pieters R, Kaspers GJ: The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer; 2005 Dec 12;93(12):1388-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.
  • Cytarabine (ara-C) is the most effective agent for the treatment of acute myeloid leukaemia (AML).
  • We determined mRNA expression of these factors using quantitative-real-time-PCR in leukemic blasts from children diagnosed with de novo AML.
  • Expression of the inactivating enzyme pyrimidine nucleotidase-I (PN-I) was 1.8-fold lower in FAB-M5 as compared to FAB-M1/2 (P=0.007).
  • In conclusion, decreased expression of hENT1, which transports ara-C across the cell membrane, appears to be a major factor in ara-C resistance in childhood AML.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacology. Cytarabine / pharmacology. Equilibrative Nucleoside Transporter 1 / physiology. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / genetics
  • [MeSH-minor] Acute Disease. Cell Membrane. Child. Drug Resistance, Neoplasm. Gene Expression Profiling. Humans. RNA, Messenger / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1999 Mar;104(3):630-9 [10086807.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1270-6 [12406912.001]
  • [Cites] Br J Haematol. 1999 Jul;106(1):78-85 [10444166.001]
  • [Cites] Klin Padiatr. 1999 Jul-Aug;211(4):239-44 [10472557.001]
  • [Cites] Leukemia. 2005 Apr;19(4):537-44 [15690069.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2879-86 [11023525.001]
  • [Cites] J Mol Diagn. 2001 May;3(2):55-61 [11333300.001]
  • [Cites] J Biol Chem. 2001 Jan 26;276(4):2914-27 [11032837.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7217-24 [11585758.001]
  • [Cites] Eur J Cancer. 2003 Mar;39(5):691-7 [12628850.001]
  • [Cites] Leuk Res. 2003 Dec;27(12):1075-6 [12921942.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7524-36 [14576856.001]
  • [Cites] Curr Opin Investig Drugs. 2003 Dec;4(12):1442-50 [14763130.001]
  • [Cites] Ann Hematol. 2004;83 Suppl 1:S108-12 [15124698.001]
  • [Cites] Cancer Res. 1978 Mar;38(3):579-85 [203385.001]
  • [Cites] J Clin Invest. 1982 Feb;69(2):479-89 [6948829.001]
  • [Cites] Mol Pharmacol. 1983 Jan;23(1):159-64 [6306421.001]
  • [Cites] Science. 1983 Aug 5;221(4610):514-9 [6306767.001]
  • [Cites] Semin Oncol. 1985 Jun;12(2 Suppl 3):65-74 [3892704.001]
  • [Cites] Ann Intern Med. 1985 Oct;103(4):620-5 [3862359.001]
  • [Cites] Cancer Res. 1985 Nov;45(11 Pt 2):5952-7 [4053067.001]
  • [Cites] Cancer Res. 1986 Mar;46(3):1079-83 [3484676.001]
  • [Cites] Pharmacol Ther. 1985;30(3):287-99 [2433703.001]
  • [Cites] Semin Oncol. 1987 Jun;14(2 Suppl 1):159-66 [3589690.001]
  • [Cites] Leukemia. 1988 May;2(5):253-60 [3287015.001]
  • [Cites] Blood. 1990 Dec 1;76(11):2327-36 [2257305.001]
  • [Cites] Cancer Res. 1991 May 15;51(10):2559-65 [2021937.001]
  • [Cites] Br J Cancer. 1991 Sep;64(3):469-74 [1911186.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2389-93 [1568208.001]
  • [Cites] Leukemia. 1993 Jul;7(7):1005-11 [7686601.001]
  • [Cites] Cancer Surv. 1993;17:123-56 [8137339.001]
  • [Cites] Leukemia. 1994 Jul;8(7):1224-9 [8035616.001]
  • [Cites] Cancer Res. 1994 Oct 15;54(20):5401-7 [7923172.001]
  • [Cites] Br J Cancer. 1994 Dec;70(6):1047-52 [7981053.001]
  • [Cites] Blood. 1995 Oct 15;86(8):3097-108 [7579404.001]
  • [Cites] Leukemia. 1995 Nov;9(11):1864-9 [7475276.001]
  • [Cites] Leuk Res. 1996 Aug;20(8):677-82 [8913321.001]
  • [Cites] Adv Cancer Res. 1998;72:197-233 [9338077.001]
  • [Cites] FEBS Lett. 1997 Dec 15;419(2-3):263-7 [9428647.001]
  • [Cites] Adv Exp Med Biol. 1998;431:667-71 [9598149.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4173-9 [9751631.001]
  • [Cites] Trends Pharmacol Sci. 1998 Oct;19(10):424-30 [9803833.001]
  • [Cites] Leuk Lymphoma. 1998 Oct;31(3-4):405-9 [9869205.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45270-5 [11584005.001]
  • [Cites] Hematol Oncol. 2001 Dec;19(4):151-7 [11754391.001]
  • [Cites] Curr Opin Oncol. 2002 Jan;14(1):3-9 [11790973.001]
  • [Cites] Leuk Res. 2002 Jul;26(7):621-9 [12008078.001]
  • [Cites] Br J Haematol. 2002 Jun;117(4):860-8 [12060121.001]
  • [Cites] Lancet Oncol. 2002 Jul;3(7):415-24 [12142171.001]
  • [Cites] Mol Cancer Ther. 2002 Apr;1(6):371-6 [12477049.001]
  • [Cites] Cancer Treat Res. 2002;112:27-47 [12481710.001]
  • [Cites] Biochem Cell Biol. 1998;76(5):761-70 [10353709.001]
  • (PMID = 16333246.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Equilibrative Nucleoside Transporter 1; 0 / RNA, Messenger; 0 / SLC29A1 protein, human; 04079A1RDZ / Cytarabine
  • [Other-IDs] NLM/ PMC2361532
  •  go-up   go-down


66. Petrovici K, Graf M, Hecht K, Reif S, Pfister K, Schmetzer H: Use of NG2 (7.1) in AML as a tumor marker and its association with a poor prognosis. Cancer Genomics Proteomics; 2010 Jul-Aug;7(4):173-80
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of NG2 (7.1) in AML as a tumor marker and its association with a poor prognosis.
  • We analyzed 70 bone marrow (BM) samples from acute myeloid leukemia (AML) patients for 11q23 aberrations and reactivity with the monoclonal antibody NG2.
  • NG2 reactivity correlated with FAB-M5 (50% positive cases, with an average of 32% NG2(+) cells), as well as with 11q23 aberrations.
  • We detected NG2(+) cells in AML cases with normal karyotype, however, not in healthy BM cells.
  • This means that NG2 qualifies as a reliable AML blast tumor marker, enabling monitoring of the course of AML independently of, although often associated with, 11q23-aberrations.
  • [MeSH-major] Antigens / analysis. Biomarkers, Tumor / analysis. Leukemia, Myeloid, Acute / metabolism. Proteoglycans / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20656983.001).
  • [ISSN] 1790-6245
  • [Journal-full-title] Cancer genomics & proteomics
  • [ISO-abbreviation] Cancer Genomics Proteomics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens; 0 / Biomarkers, Tumor; 0 / Proteoglycans; 0 / chondroitin sulfate proteoglycan 4
  •  go-up   go-down


67. Dorfman DM, Hornick JL, Shahsafaei A, Freeman GJ: The phosphatidylserine receptors, T cell immunoglobulin mucin proteins 3 and 4, are markers of histiocytic sarcoma and other histiocytic and dendritic cell neoplasms. Hum Pathol; 2010 Oct;41(10):1486-94
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because TIM-4 is expressed by macrophages and dendritic cells in human tissue, we examined its expression in a range of histiocytic and dendritic cell neoplasms and found moderate to strong immunohistochemical staining in cases of juvenile xanthogranuloma and histiocytic sarcoma, and lower level staining in interdigitating dendritic cell sarcoma, Langerhans cell histiocytosis, acute monocytic leukemia (leukemia cutis), and blastic plasmacytoid dendritic cell neoplasm (hematodermic tumor).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] J Immunol. 2010 Feb 15;184(4):1918-30 [20083673.001]
  • [Cites] Eur J Immunol. 2009 Sep;39(9):2492-501 [19676072.001]
  • [Cites] Nat Immunol. 2001 Jan;2(1):83-8 [11135583.001]
  • [Cites] Leukemia. 2002 Aug;16(8):1484-9 [12145689.001]
  • [Cites] Leuk Res. 2002 Dec;26(12):1131-3 [12443887.001]
  • [Cites] Am J Pathol. 2003 May;162(5):1539-44 [12707037.001]
  • [Cites] Lancet Oncol. 2004 Apr;5(4):248-50 [15050956.001]
  • [Cites] Cell. 2004 May 28;117(5):663-76 [15163413.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1133-44 [15316312.001]
  • [Cites] Am J Clin Pathol. 2004 Aug;122(2):292-7 [15323146.001]
  • [Cites] Blood. 2005 May 1;105(9):3488-92 [15650059.001]
  • [Cites] Pediatr Blood Cancer. 2005 Sep;45(3):256-64 [15547923.001]
  • [Cites] J Immunol. 2006 Jul 1;177(1):280-9 [16785523.001]
  • [Cites] Am J Surg Pathol. 2006 Jul;30(7):802-10 [16819321.001]
  • [Cites] Nature. 2007 Sep 27;449(7161):473-7 [17851532.001]
  • [Cites] Am J Clin Pathol. 2007 Nov;128(5):776-82 [17951199.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1141-3 [18006747.001]
  • [Cites] Immunity. 2007 Dec;27(6):927-40 [18082433.001]
  • [Cites] Am J Surg Pathol. 2008 Apr;32(4):615-9 [18277880.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5433-9 [18272816.001]
  • [Cites] N Engl J Med. 2008 Aug 14;359(7):736-47 [18703477.001]
  • [Cites] Blood. 2009 Apr 16;113(16):3821-30 [19224762.001]
  • [Cites] Immunol Rev. 2009 May;229(1):259-70 [19426227.001]
  • [Cites] J Virol. 2009 Sep;83(18):9122-30 [19587053.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):861-71 [12598320.001]
  • (PMID = 20656318.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / P01 AI054456; United States / NIAID NIH HHS / AI / P01 AI054456; United States / NIAID NIH HHS / AI / P01 AI054456-01; United States / NIAID NIH HHS / AI / P01 AI054456-02; United States / NIAID NIH HHS / AI / P01 AI054456-03; United States / NIAID NIH HHS / AI / P01 AI054456-04; United States / NIAID NIH HHS / AI / P01 AI054456-05; United States / NIAID NIH HHS / AI / P01 AI054456-06A1; United States / NIAID NIH HHS / AI / P01 AI054456-07; United States / NIAID NIH HHS / AI / R01 AI089955; United States / NIAID NIH HHS / AI / R01 AI089955-01; United States / NIAID NIH HHS / AI / R01 AI089955-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HAVCR2 protein, human; 0 / Membrane Proteins; 0 / Receptors, Cell Surface; 0 / TIMD4 protein, human; 0 / phosphatidylserine receptor
  • [Other-IDs] NLM/ NIHMS298185; NLM/ PMC3115740
  •  go-up   go-down


68. Ahn HJ, Kim JY, Ryu KJ, Nam HW: STAT6 activation by Toxoplasma gondii infection induces the expression of Th2 C-C chemokine ligands and B clade serine protease inhibitors in macrophage. Parasitol Res; 2009 Oct;105(5):1445-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Toxoplasma gondii provoked rapid and sustained nuclear translocation of signal transducer and activator of transcription (STAT) 6, a central mediator of interleukin (IL)-4, in macrophage-differentiated human acute monocytic leukemia cells without exogenous IL-4 in western blot and immunofluorescence assay.

  • MedlinePlus Health Information. consumer health - Toxoplasmosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6115-9 [8100999.001]
  • [Cites] PLoS Pathog. 2005 Nov;1(3):e24 [16304607.001]
  • [Cites] J Immunol. 2006 Jan 15;176(2):819-26 [16393965.001]
  • [Cites] J Clin Invest. 2002 May;109(9):1133-7 [11994400.001]
  • [Cites] Cell Mol Life Sci. 2008 Jun;65(12):1900-15 [18327664.001]
  • [Cites] Br J Cancer. 2000 Feb;82(4):981-9 [10732775.001]
  • [Cites] Korean J Parasitol. 2009 Jun;47(2):117-24 [19488417.001]
  • [Cites] FEMS Immunol Med Microbiol. 2003 Dec 5;39(3):193-203 [14642303.001]
  • [Cites] J Immunol. 2001 Aug 15;167(4):2193-201 [11490005.001]
  • [Cites] Microbes Infect. 2007 Nov-Dec;9(14-15):1652-61 [18024121.001]
  • [Cites] Mol Cell Biol. 2002 Jan;22(1):117-26 [11739727.001]
  • [Cites] Int J Parasitol. 2003 Jul 30;33(8):833-44 [12865083.001]
  • [Cites] J Cell Physiol. 2003 Nov;197(2):157-68 [14502555.001]
  • [Cites] Med Sci (Paris). 2008 Feb;24(2):191-6 [18272082.001]
  • [Cites] Int Immunopharmacol. 2006 Mar;6(3):485-93 [16428084.001]
  • [Cites] J Immunol. 2001 Feb 15;166(4):2173-7 [11160269.001]
  • [Cites] J Cell Sci. 2001 Oct;114(Pt 19):3495-505 [11682609.001]
  • [Cites] Blood. 2004 Jul 15;104(2):543-9 [15044251.001]
  • [Cites] Biochemistry. 2003 Jun 24;42(24):7381-9 [12809493.001]
  • [Cites] J Immunol. 2005 Mar 15;174(6):3148-52 [15749841.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Sep 28;287(3):630-5 [11563841.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15137-42 [11752460.001]
  • [Cites] Eur J Immunol. 2001 Feb;31(2):333-44 [11180096.001]
  • [Cites] Infect Immun. 2002 Dec;70(12):6933-9 [12438372.001]
  • [Cites] Cell Mol Life Sci. 2004 Feb;61(3):301-25 [14770295.001]
  • [Cites] Immunology. 2009 Jun;127(2):187-95 [18795973.001]
  • [Cites] Mol Immunol. 2002 May;38(12-13):881-5 [12009564.001]
  • [Cites] Nature. 2007 Jan 18;445(7125):324-7 [17183270.001]
  • [Cites] J Biol Chem. 2005 Mar 18;280(11):9761-4 [15677460.001]
  • [Cites] Trends Immunol. 2004 Nov;25(11):601-9 [15489189.001]
  • [Cites] Parasite Immunol. 2004 Oct;26(10 ):419-22 [15752119.001]
  • [Cites] Korean J Parasitol. 1999 Dec;37(4):249-56 [10634041.001]
  • [Cites] J Exp Med. 2001 Jul 16;194(2):181-8 [11457893.001]
  • [Cites] Eur J Biochem. 2001 Nov;268(22):5868-75 [11722574.001]
  • [Cites] Infect Immun. 2002 Feb;70(2):859-68 [11796621.001]
  • [Cites] J Immunol. 1999 Jun 15;162(12):7369-75 [10358188.001]
  • (PMID = 19655172.001).
  • [ISSN] 1432-1955
  • [Journal-full-title] Parasitology research
  • [ISO-abbreviation] Parasitol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chemokines, CC; 0 / STAT6 Transcription Factor; 0 / STAT6 protein, human; 0 / Serpins
  •  go-up   go-down


69. Laengle UW, Markstein R, Cazaubon C, Roman D: Antiglaucoma drug GLC756 and its effect on cellular cAMP and tumor necrosis factor alpha release in vitro of activated human monocytic leukemia cells. Jpn J Ophthalmol; 2009 Mar;53(2):159-63
Hazardous Substances Data Bank. BETAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiglaucoma drug GLC756 and its effect on cellular cAMP and tumor necrosis factor alpha release in vitro of activated human monocytic leukemia cells.
  • The present study describes the effects of GLC756 on cellular adenosine 3', 5'-cyclic monophosphate (cAMP) in relation to TNF-alpha production on LPS-stimulated human acute monocytic leukemia cells.
  • METHODS: A human peripheral blood acute monocytic leukemia cell line (THP-1) was activated via LPS.
  • [MeSH-major] Antihypertensive Agents / pharmacology. Cyclic AMP / metabolism. Leukemia, Monocytic, Acute / drug therapy. Quinolines / pharmacology. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Front Biosci. 1997 Jan 01;2:d12-26 [9159205.001]
  • [Cites] Arthritis Res Ther. 2003;5(6):R317-28 [14680506.001]
  • [Cites] J Neuroimmunol. 2002 Nov;132(1-2):34-40 [12417431.001]
  • [Cites] Rev Physiol Biochem Pharmacol. 1999;135:67-104 [9932481.001]
  • [Cites] Genome Biol. 2006;7(2):R11 [16507166.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 Oct;279(4):L615-7 [11000119.001]
  • [Cites] Eur J Ophthalmol. 2006 May-Jun;16(3):401-6 [16761241.001]
  • [Cites] Cell Immunol. 1989 May;120(2):291-300 [2541929.001]
  • [Cites] J Invest Dermatol. 2005 Oct;125(4):783-9 [16185279.001]
  • [Cites] J Immunol. 1995 Nov 15;155(10):4909-16 [7594495.001]
  • [Cites] Neuroreport. 2000 Nov 9;11(16):3565-8 [11095519.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Oct;291(1):258-64 [10490912.001]
  • [Cites] J Immunol. 2002 Oct 1;169(7):3801-10 [12244175.001]
  • [Cites] Trends Pharmacol Sci. 1999 Feb;20(2):66-73 [10101967.001]
  • [Cites] J Neurochem. 2004 Apr;89(2):474-83 [15056290.001]
  • [Cites] Int Immunol. 2005 May;17 (5):599-606 [15802305.001]
  • [Cites] Infect Immun. 1989 Sep;57(9):2837-41 [2547721.001]
  • [Cites] J Ocul Pharmacol. 1992 Winter;8(4):285-94 [1484260.001]
  • [Cites] Crit Care Med. 1997 Nov;25(11):1855-61 [9366770.001]
  • [Cites] Gut. 1998 Apr;42(4):477-84 [9616307.001]
  • [Cites] Jpn J Ophthalmol. 1996;40(2):167-73 [8876383.001]
  • [Cites] Crit Rev Clin Lab Sci. 1999 Aug;36(4):275-328 [10486703.001]
  • [Cites] Eur J Immunol. 1996 Jul;26(7):1580-6 [8766564.001]
  • [Cites] Ophthalmology. 1989 Mar;96(3):327-35 [2710524.001]
  • [Cites] Clin Immunol Immunopathol. 1990 May;55(2):157-70 [2182227.001]
  • [Cites] Placenta. 2005 Sep-Oct;26(8-9):654-60 [16085044.001]
  • [Cites] Int J Immunopharmacol. 1993 Feb;15(2):219-28 [8096834.001]
  • [Cites] Int Ophthalmol. 1996-1997;20(1-3):57-62 [9112165.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1995 Jan;36(1):247-51 [7822153.001]
  • [Cites] Scand J Immunol. 1991 Jul;34(1):121-5 [1648785.001]
  • [Cites] Arch Ophthalmol. 1994 Nov;112(11):1437-45 [7980133.001]
  • [Cites] Exp Eye Res. 2006 Nov;83(5):1246-51 [16938291.001]
  • [Cites] J Neural Transm (Vienna). 1996;103(1-2):17-30 [9026371.001]
  • [Cites] Ophthalmology. 1995 Sep;102(9):1291-7 [9097765.001]
  • (PMID = 19333701.001).
  • [ISSN] 1613-2246
  • [Journal-full-title] Japanese journal of ophthalmology
  • [ISO-abbreviation] Jpn. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antihypertensive Agents; 0 / Glucocorticoids; 0 / Lipopolysaccharides; 0 / Ophthalmic Solutions; 0 / Quinolines; 0 / Receptors, Dopamine D1; 0 / Receptors, Dopamine D2; 0 / SDZ GLC 756; 0 / Tumor Necrosis Factor-alpha; 9842X06Q6M / Betamethasone; E0399OZS9N / Cyclic AMP
  •  go-up   go-down


70. Murati A, Adélaïde J, Quilichini B, Rémy V, Sainty D, Stoppa AM, Bernard P, Olschwang S, Birnbaum D, Chaffanet M, Mozziconacci MJ: New types of MYST3-CBP and CBP-MYST3 fusion transcripts in t(8;16)(p11;p13) acute myeloid leukemias. Haematologica; 2007 Feb;92(2):262-3
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New types of MYST3-CBP and CBP-MYST3 fusion transcripts in t(8;16)(p11;p13) acute myeloid leukemias.
  • The t(8;16)(p11;p13) translocation, associated with poor prognosis acute monocytic leukemia, fuses MYST3 on chromosome region 8p11 to CBP on chromosome region 16p13.
  • [MeSH-major] Carrier Proteins / genetics. Chromosomes, Human, Pair 16. Chromosomes, Human, Pair 8. Histone Acetyltransferases / genetics. Leukemia, Myeloid, Acute / genetics. Oncogene Proteins, Fusion / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17296583.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / DNA Primers; 0 / Oncogene Proteins, Fusion; EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / KAT6A protein, human; W980KJ009P / Corticosterone
  •  go-up   go-down


71. Arias F, Vives R, Gómez-Dorronsoro ML: Cutaneous nodes in a patient with advanced papillary carcinoma of the thyroid. Clin Transl Oncol; 2006 Sep;8(9):692-3
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Leukemia as a second malignancy after treatment of thyroid cancer is also rare.
  • Our patient is unusual in that she showed multisystem involvement at the time of hospital admission, and the specific skin lesions were the first sign of her acute monocytic leukemia.
  • [MeSH-major] Carcinoma, Papillary / radiotherapy. Leukemia, Monocytic, Acute / diagnosis. Leukemia, Radiation-Induced / diagnosis. Neoplasms, Second Primary / diagnosis. Skin Neoplasms / diagnosis. Thyroid Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatology. 1999;199(4):349-52 [10640848.001]
  • [Cites] Ann Hematol. 1998 Jun;76(6):271-2 [9692815.001]
  • [Cites] Semin Dermatol. 1994 Sep;13(3):223-30 [7986692.001]
  • [Cites] J Am Acad Dermatol. 1997 Apr;36(4):531-7 [9092737.001]
  • [Cites] Br J Haematol. 1988 Jun;69(2):247-52 [3291931.001]
  • [Cites] J Am Acad Dermatol. 1993 May;28(5 Pt 2):884-8 [8491887.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):893-4 [10084909.001]
  • (PMID = 17005473.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


72. Lu J, Sheng GY, Zou X, Xu XJ, Zhao XM, Bai ST, Xu PR: [Effects of FMS-like tyrosine kinase 3 targeted RNA interference on proliferation and apoptosis of acute monocytic leukemia cell line THP-1]. Zhonghua Er Ke Za Zhi; 2007 Aug;45(8):615-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of FMS-like tyrosine kinase 3 targeted RNA interference on proliferation and apoptosis of acute monocytic leukemia cell line THP-1].
  • OBJECTIVE: FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase that is constitutively activated in (70-90)% pediatric patients with acute myeloid leukemia (AML) and appears to confer an adverse prognosis.
  • The aim of the present study was to investigate the efficacy of suppression of FLT3 induced by small hairpin interfering RNA (shRNA) on myeloproliferation and apoptosis in an acute monocytic leukemia (AMOL) cell line THP-1.
  • FLT3-shRNA induced the inhibition of cell cycle from G(0)/G(1) phase to S phase, the percentage of sub-G(0)/G(1) phase (65.71 +/- 4.47)% was higher than those in the PBS-control group (52.23 +/- 2.98)%, NC-shRNA control group (51.81 +/- 1.44)%, P < 0.01; the percentage of S phase (25.11 +/- 2.70)% was lower than those in the PBS-control group (34.41 +/- 4.07)% and NC-shRNA control group (32.50 +/- 1.46)%, P < 0.05.
  • [MeSH-major] Apoptosis / drug effects. Cell Proliferation / drug effects. Leukemia, Monocytic, Acute / pathology. RNA, Small Interfering / pharmacology. fms-Like Tyrosine Kinase 3 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021537.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Small Interfering; EC 2.7.1.- / TYRO3 protein, human; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


73. Fan LP, Shen JZ, Fu HY, Zhou HR, Shen SF, Yu AF: [Effect of epigallocatechin-3-galate on human acute monocytic leukemia cell line U937 and its relevant mechanism]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr;18(2):286-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of epigallocatechin-3-galate on human acute monocytic leukemia cell line U937 and its relevant mechanism].
  • The purpose of this study was to explore the effect of epigallocatechin-3-galate (EGCG) on acute monocytic leukemia cell line U937 and its relevant mechanism.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20416153.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37 / DNA (cytosine-5-)-methyltransferase 1; EC 2.1.1.37 / DNA methyltransferase 3A; EC 2.1.1.37 / DNA methyltransferase 3B
  •  go-up   go-down


74. Kurosu T, Tsuji K, Ohki M, Miki T, Yamamoto M, Kakihana K, Koyama T, Taniguchi S, Miura O: A variant-type MLL/SEPT9 fusion transcript in adult de novo acute monocytic leukemia (M5b) with t(11;17)(q23;q25). Int J Hematol; 2008 Sep;88(2):192-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A variant-type MLL/SEPT9 fusion transcript in adult de novo acute monocytic leukemia (M5b) with t(11;17)(q23;q25).
  • As a result of recurrent chromosomal translocations in acute leukemias, the mixed-lineage-leukemia (MLL) gene fuses with a variety of partner genes, which include several members of the septin gene family.
  • Herein, we report a case of de novo acute monocytic leukemia (M5b) with t(11;17)(q23;q25).
  • Relapsing after a very short complete remission, the leukemia progressed rapidly and became fatal in spite of intensive therapies including hematopoietic stem cell transplantation.
  • It is thus suggested that, in common with the original MLL/SEPT9 cases, monocytic differentiation and a poor prognosis may also be associated with acute myeloid leukemia with the variant MLL/SEPT9 fusion transcript.
  • [MeSH-major] GTP Phosphohydrolases / genetics. Leukemia, Monocytic, Acute / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Oncogene Proteins, Fusion / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2004 May;18(5):998-1005 [14999297.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):99-110 [12957285.001]
  • [Cites] Br J Haematol. 1996 Jun;93(4):966-72 [8703835.001]
  • [Cites] Oncogene. 2005 Jan 6;24(1):65-76 [15558029.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):919-29 [15761502.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):449-54 [15626757.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4688-700 [15782116.001]
  • [Cites] Blood. 1999 May 1;93(9):3074-80 [10216104.001]
  • [Cites] Genomics. 2000 Jan 15;63(2):165-72 [10673329.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Nov;45(11):1041-9 [16897742.001]
  • [Cites] Leukemia. 2004 Sep;18(9):1522-30 [15322560.001]
  • [Cites] Oncogene. 2006 Oct 5;25(45):6147-52 [16682951.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2434-9 [11290608.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55895-904 [15485874.001]
  • [Cites] Int J Hematol. 2005 Jul;82(1):9-20 [16105754.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4261-5 [10485469.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2484-90 [15956279.001]
  • [Cites] J Pathol. 2004 Nov;204(4):489-505 [15495264.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 26;95(11):6413-8 [9600980.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):197-207 [14522254.001]
  • [Cites] Int J Hematol. 2002 Jun;75(5):503-7 [12095151.001]
  • [Cites] Leukemia. 2006 Feb;20(2):218-23 [16341046.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):856-66 [16424018.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Sep;32(1):82-8 [11477664.001]
  • [Cites] Oncogene. 2001 Sep 13;20(41):5930-9 [11593400.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5695-707 [11607819.001]
  • [Cites] Eur J Clin Invest. 2004 Aug;34 Suppl 2:12-24 [15291802.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2179-87 [12727837.001]
  • [Cites] Leuk Res. 2007 Aug;31(8):1145-8 [17250889.001]
  • [Cites] J Pathol. 2003 Dec;201(4):581-8 [14648661.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 25;96(11):6428-33 [10339604.001]
  • [Cites] Semin Hematol. 1999 Oct;36(4 Suppl 7):59-72 [10595755.001]
  • [Cites] Br J Haematol. 1999 Sep;106(3):614-26 [10468849.001]
  • [Cites] Gene. 2002 Feb 20;285(1-2):79-89 [12039034.001]
  • [Cites] Leukemia. 2006 May;20(5):777-84 [16511515.001]
  • (PMID = 18642054.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / MLL protein, human; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 3.6.1.- / GTP Phosphohydrolases; EC 3.6.1.- / SEPT9 protein, human; EC 3.6.1.- / Septins
  •  go-up   go-down


75. Sato Y, Yokoyama A, Shibata K, Akimoto Y, Ogino S, Nodasaka Y, Kohgo T, Tamura K, Akasaka T, Uo M, Motomiya K, Jeyadevan B, Ishiguro M, Hatakeyama R, Watari F, Tohji K: Influence of length on cytotoxicity of multi-walled carbon nanotubes against human acute monocytic leukemia cell line THP-1 in vitro and subcutaneous tissue of rats in vivo. Mol Biosyst; 2005 Jul;1(2):176-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of length on cytotoxicity of multi-walled carbon nanotubes against human acute monocytic leukemia cell line THP-1 in vitro and subcutaneous tissue of rats in vivo.
  • In this paper, we investigated the activation of the human acute monocytic leukemia cell line THP-1 in vitro and the response in subcutaneous tissue in vivo to CNTs of different lengths.
  • [MeSH-minor] Animals. Cell Line, Tumor. Culture Media / chemistry. Culture Media / pharmacology. Humans. Inflammation / etiology. Leukemia, Monocytic, Acute / metabolism. Leukemia, Monocytic, Acute / pathology. Male. Microscopy, Electron, Scanning. Microscopy, Electron, Transmission. Nanostructures / chemistry. Nanostructures / ultrastructure. Nanotechnology / methods. Rats. Rats, Wistar. Spectrophotometry, Infrared. Subcutaneous Tissue / pathology. Subcutaneous Tissue / ultrastructure. Tumor Necrosis Factor-alpha / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16880981.001).
  • [ISSN] 1742-206X
  • [Journal-full-title] Molecular bioSystems
  • [ISO-abbreviation] Mol Biosyst
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Culture Media; 0 / Nanotubes, Carbon; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


76. Imataki O, Ohnishi H, Yamaoka G, Arai T, Kitanaka A, Kubota Y, Kushida Y, Ishida T, Tanaka T: Lineage switch from precursor B cell acute lymphoblastic leukemia to acute monocytic leukemia at relapse. Int J Clin Oncol; 2010 Feb;15(1):112-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lineage switch from precursor B cell acute lymphoblastic leukemia to acute monocytic leukemia at relapse.
  • A lineage switch in leukemia, in which the leukemic cell lineage at onset converts to another lineage at a later time, is an uncommon type of hybrid (mixed) leukemia regarded as a variation of bilineage leukemia.
  • We present a case of a 60-year-old female diagnosed with precursor B cell acute lymphoblastic leukemia (ALL), whose markers in flow cytometry shifted from their original status of CD19+, 22+, 79a+, 13+, HLA-DR+, and TdT+.
  • Residual disease was proved by biopsy and pathologically shown to have an immature phenotype of CD5+, CD10-, CD20-, CD79a- and myeloperoxidase negativity.
  • Two weeks after liver biopsy, blast cells progressively appeared in the peripheral blood; these cells had a monocytoid morphology and phenotype (CD13, 14) but were accompanied by myeloid (CD33) and lymphoid (CD2, 4, 20) cells.
  • This phenotypical conversion from B-ALL to hybrid leukemia featuring monocytoid characteristics is known as a lineage switch.
  • [MeSH-major] Leukemia, Biphenotypic, Acute / pathology. Leukemia, Monocytic, Acute / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1995 Dec;9(12):2023-6 [8609712.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):311-21 [15803157.001]
  • [Cites] Br J Haematol. 1987 Mar;65(3):261-4 [3552021.001]
  • [Cites] Leuk Lymphoma. 2005 Aug;46(8):1223-7 [16085566.001]
  • [Cites] Blood. 1984 Sep;64(3):701-6 [6590097.001]
  • [Cites] Blood. 1989 Nov 1;74(6):2088-95 [2553159.001]
  • [Cites] Haematologica. 2004 Aug;89(8):ECR28 [15339697.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Jan 15;164(2):118-21 [16434313.001]
  • [Cites] Am J Hematol. 2000 Sep;65(1):72-4 [10936868.001]
  • [Cites] Clin Haematol. 1986 Aug;15(3):811-27 [3536242.001]
  • [Cites] Blood Rev. 1988 Mar;2(1):9-15 [3289656.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Jul 15;168(2):146-9 [16843104.001]
  • [Cites] Br J Haematol. 1993 May;84(1):49-60 [7687860.001]
  • (PMID = 20066454.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


77. Mezzanotte L, Fazzina R, Michelini E, Tonelli R, Pession A, Branchini B, Roda A: In vivo bioluminescence imaging of murine xenograft cancer models with a red-shifted thermostable luciferase. Mol Imaging Biol; 2010 Aug;12(4):406-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Conventional in vivo bioluminescence imaging using wild-type green-emitting luciferase is limited by absorption and scattering of the bioluminescent signal through tissues.
  • METHODS: Human hepatoblastoma cell line (HepG2) and human acute monocytic leukemia cell line (Thp1) cells were genetically engineered using retroviral vector technology to stably express the red-shifted or the wild-type green luciferase.
  • A xenograft model of liver cancer was established by subcutaneous injection of the HepG2-engineered cells in the flank regions of mice, and a leukemia model was generated by intravenous injection of the engineered Thp1 cells.
  • CONCLUSION: Two different bioluminescent mouse cancer models demonstrate the utility of a new red-shifted thermostable luciferase, Ppy RE-TS, that improved the in vivo imaging performance when compared with wild-type P.
  • While wild-type luciferase is currently a popular reporter for in vivo imaging methods, this study demonstrates the potential of red-emitting firefly luciferase mutants to enhance the performance of bioluminescence imaging experiments.
  • [MeSH-minor] Absorption / drug effects. Animals. Benzothiazoles / administration & dosage. Benzothiazoles / pharmacology. Cell Count. Cell Line, Tumor. Color. Disease Progression. Enzyme Stability / drug effects. Hep G2 Cells. Humans. Injections, Intraperitoneal. Kinetics. Mice. Photons. Substrate Specificity / drug effects. Transfection. Tumor Burden / drug effects

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biomed Opt. 2007 Sep-Oct;12(5):054018 [17994906.001]
  • [Cites] J Virol. 2000 Nov;74(21):10074-80 [11024136.001]
  • [Cites] Clin Exp Metastasis. 2007;24(8):699-705 [17972147.001]
  • [Cites] Leukemia. 2006 Jul;20(7):1307-10 [16617320.001]
  • [Cites] Nat Biotechnol. 2005 Mar;23(3):313-20 [15765087.001]
  • [Cites] Mol Imaging. 2004 Apr;3(2):117-24 [15296676.001]
  • [Cites] J Biomed Opt. 2005 Jul-Aug;10(4):41210 [16178634.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11859-66 [18089816.001]
  • [Cites] Photochem Photobiol Sci. 2009 Jan;8(1):52-6 [19247529.001]
  • [Cites] Nat Methods. 2007 Aug;4(8):641-3 [17618292.001]
  • [Cites] J Pathol. 2005 Jan;205(2):194-205 [15641018.001]
  • [Cites] Curr Opin Biotechnol. 2009 Feb;20(1):45-53 [19233638.001]
  • [Cites] Annu Rev Biomed Eng. 2002;4:235-60 [12117758.001]
  • [Cites] Appl Opt. 2006 May 10;45(14):3390-4 [16676048.001]
  • [Cites] Mol Ther. 2005 Mar;11(3):435-43 [15727940.001]
  • [Cites] Phys Med Biol. 2005 Dec 7;50(23):5421-41 [16306643.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 May;35(5):999-1007 [18180921.001]
  • [Cites] Anal Biochem. 2007 Feb 15;361(2):253-62 [17181991.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Dec;35(12):2275-85 [18661130.001]
  • [Cites] Anal Biochem. 2006 Aug 1;355(1):90-4 [16737677.001]
  • (PMID = 19937390.001).
  • [ISSN] 1860-2002
  • [Journal-full-title] Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
  • [ISO-abbreviation] Mol Imaging Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzothiazoles; 0 / D-luciferin; EC 1.13.12.- / Luciferases
  •  go-up   go-down


78. Metzelder SK, Reinke C, Walthers EM, Barth P, Vogelmeier C, Neubauer A, Bals R: ["Malignant" ARDS]. Internist (Berl); 2009 Oct;50(10):1272, 1274-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acute respiratory failure and the "acute respiratory distress syndrome" (ARDS) are frequent medical conditions in critically ill patients.
  • The first patient was diagnosed with an acute myeloic leukemia M5 (FAB).
  • These case reports show that in addition to the classical causes of ARDS, specific disease entities can mimic this form of respiratory failure.
  • Beside solid cancers and lymphomas, acute and progressive forms of inflammatory, parenchymal lung diseases (such as acute interstitial pneumonitis, acute eosinophilic pneumonia, diffuse alveolar hemorrhagia, and acute hypersensitivity pneumonitis) can manifest with this picture.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Lung Diseases, Interstitial / complications. Lung Diseases, Interstitial / diagnosis. Lung Neoplasms / complications. Lung Neoplasms / diagnosis. Respiratory Distress Syndrome, Adult / diagnosis. Respiratory Distress Syndrome, Adult / etiology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Interstitial Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Crit Care. 1994 Mar;9(1):72-81 [8199655.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Aug;28(4):415-24 [10862050.001]
  • [Cites] Chest. 2004 Apr;125(4):1530-5 [15078770.001]
  • [Cites] Thorax. 2002 May;57(5):452-8 [11978926.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Jan 15;165(2):277-304 [11790668.001]
  • (PMID = 19562262.001).
  • [ISSN] 1432-1289
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


79. Haouari O, Fardeau ML, Cayol JL, Casiot C, Elbaz-Poulichet F, Hamdi M, Joseph M, Ollivier B: Desulfotomaculum hydrothermale sp. nov., a thermophilic sulfate-reducing bacterium isolated from a terrestrial Tunisian hot spring. Int J Syst Evol Microbiol; 2008 Nov;58(Pt 11):2529-35
StrainInfo. culture/stock collections - online strain list (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A novel strictly anaerobic, moderately thermophilic, sulfate-reducing bacterium, designated strain Lam5(T), was isolated from a hot spring in north-east Tunisia and was characterized phenotypically and phylogenetically.
  • The isolate stained Gram-negative but had a Gram-positive-type cell wall.
  • Strain Lam5(T) grew anaerobically at 40-60 degrees C (optimally at 55 degrees C) and at pH 5.8-8.2 (optimally at pH 7.1); it did not require NaCl but tolerated concentrations up to 1.5 % (w/v).
  • Phylogenetic analysis based on 16S rRNA gene sequencing showed that strain Lam5(T) was a member of the genus Desulfotomaculum, with Desulfotomaculum putei as its closest relative (96 % similarity to the type strain).
  • On the basis of genotypic, phenotypic and phylogenetic data, strain Lam5(T) represents a novel species of the genus Desulfotomaculum, for which the name Desulfotomaculum hydrothermale sp. nov. is proposed.
  • The type strain is Lam5(T) (=DSM 18033(T) =JCM 13992(T)).

  • National BioResource Project. culture/stock collections - NBRP resources .
  • SILVA. SILVA SSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18984688.001).
  • [ISSN] 1466-5026
  • [Journal-full-title] International journal of systematic and evolutionary microbiology
  • [ISO-abbreviation] Int. J. Syst. Evol. Microbiol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ EF081293/ EF494253
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / DNA, Ribosomal; 0 / RNA, Ribosomal, 16S; 0 / Sulfates
  •  go-up   go-down


80. Pullarkat V, Veliz L, Chang K, Mohrbacher A, Teotico AL, Forman SJ, Slovak ML: Therapy-related, mixed-lineage leukaemia translocation-positive, monoblastic myeloid sarcoma of the uterus. J Clin Pathol; 2007 May;60(5):562-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related, mixed-lineage leukaemia translocation-positive, monoblastic myeloid sarcoma of the uterus.
  • Myeloid sarcomas are tumour masses of myeloid leukaemic cells at extramedullary sites.
  • These tumours can, on occasion, occur without concurrent or antecedent leukaemia.
  • Myeloid sarcomas have been described at unusual locations including the female genital tract.
  • An unusual case of therapy-related acute myeloid leukaemia (t-AML) presenting as isolated monoblastic myeloid sarcoma of the uterus in a patient who had received adjuvant chemotherapy for breast cancer is presented.
  • Fluorescence in situ hybridisation analysis performed on paraffin-wax-embedded tumour tissue revealed a mixed-lineage leukaemia (MLL) gene rearrangement, supporting the association of this malignancy with prior chemotherapy.
  • This case illustrates that t-AML can rarely present as isolated extramedullary tumours, and the detection of specific chromosomal abnormalities in these myeloid sarcomas can be useful for risk assessment and guiding definitive therapy.

  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2000 Nov;114(5):807-11 [11068557.001]
  • [Cites] Leuk Lymphoma. 2001 Apr;41(3-4):255-76 [11378539.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):1967-72 [12057901.001]
  • [Cites] Leuk Lymphoma. 2002 Nov;43(11):2151-3 [12533040.001]
  • [Cites] Int J Surg Pathol. 2003 Oct;11(4):271-82 [14615822.001]
  • [Cites] Leukemia. 2005 Feb;19(2):183-90 [15618964.001]
  • [Cites] Urology. 1986 Mar;27(3):268-70 [3082059.001]
  • [Cites] Gynecol Oncol. 1992 Jul;46(1):128-37 [1634133.001]
  • [Cites] Blood. 1993 Dec 15;82(12):3705-11 [8260707.001]
  • [Cites] Am J Clin Pathol. 1995 Oct;104(4):431-43 [7572794.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1156-65 [9331287.001]
  • [Cites] Leuk Res. 2004 Nov;28(11):1165-9 [15380340.001]
  • (PMID = 17513515.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA030206; United States / NCI NIH HHS / CA / 2 P01 CA030206-24A1; United States / NCI NIH HHS / CA / 5P30 CA33572
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1994540
  •  go-up   go-down


81. Clark BR, Ferketich AK, Fisher JL, Ruymann FB, Harris RE, Wilkins JR 3rd: Evidence of population mixing based on the geographical distribution of childhood leukemia in Ohio. Pediatr Blood Cancer; 2007 Nov;49(6):797-802
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence of population mixing based on the geographical distribution of childhood leukemia in Ohio.
  • BACKGROUND: This ecologic study examined the geographic distribution of childhood leukemias in Ohio, 1996-2000, among children aged 0-19 for evidence that population mixing may be a factor.
  • RESULTS: Of the 585 cases, 73.3% were acute lymphocytic leukemia (ALL), 16.6% acute myelogenous leukemia (AML), 3.2% acute monocytic leukemia (AMoL), and 2.6% chronic myelogenous leukemia (CML).
  • Rates for total leukemia burden were significantly below national levels for all races (P = 0.00001), likely due to poor ascertainment of cases.
  • Yearly incidence rates for 1996-2000 were stable for ALL and AML; CML rates declined over the period.
  • Based on 2000 Census and intercensal population estimates for 1996-2000, statistically higher rates for ALL were noted for counties experiencing >10% population change 1990-2000 (P < 0.05), especially for ages 1-4 (P < 0.03) in counties with 10-20% growth.
  • Counties 67.9-99.2% urban experienced fewer than expected cases of AML + AMoL (P < 0.06).
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / epidemiology. Leukemia, Myeloid, Acute / epidemiology. Population Density. Population Dynamics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Rural Population. Urban Population


82. Lapillonne H, Renneville A, Auvrignon A, Flamant C, Blaise A, Perot C, Lai JL, Ballerini P, Mazingue F, Fasola S, Dehée A, Bellman F, Adam M, Labopin M, Douay L, Leverger G, Preudhomme C, Landman-Parker J: High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol; 2006 Apr 1;24(10):1507-15
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.
  • PURPOSE: To determine whether minimal residual disease (MRD) measured by Wilms' tumor gene 1 (WT1) expression is a prognostic marker in pediatric acute myeloid leukemia (AML), we quantified WT1 transcript by real-time quantitative-polymerase chain reaction in 92 AML at diagnosis and during follow-up.
  • PATIENTS AND METHODS: Patients (median age, 6 years; cytogenetics, favorable 27%, intermediate 59%, poor 13%) were treated between 1995 and 2002 and enrolled in Leucémie aiguë Myéloblastique Enfant (LAME) 89/91, LAME 99 pilot study and Acute Promyelocytic Leukemia French collaborative protocols.
  • RESULTS: At diagnosis, WT1 overexpression was detected in 78% of patients (72 of 92 patients; median copy ratio, 2231).
  • The WT1 values were significantly higher (P = .01) in favorable cytogenetics and lower (P < .0001) in M5-FAB subtype, 11q23 rearrangements (P < .001), and infants (P = .003) and demonstrate a strong correlation with fusion transcript AML1-ETO, PML-RARalpha expression.
  • CONCLUSION: WT1 quantification is an informative molecular marker for MRD in pediatric AML and is now performed as prospective analysis in ELAM02 protocol.
  • [MeSH-major] Genes, Wilms Tumor. Leukemia, Myeloid, Acute / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575000.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
  •  go-up   go-down


83. Sajid N, Ahmed N, Khan SR: Congenital leukaemia. J Coll Physicians Surg Pak; 2005 Jan;15(1):52-4
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital leukaemia.
  • This is a case series of three infants who presented with pallor, bruises, and rashes in first month of their life with non specific symptomatology and were diagnosed to have congenital leukaemia.
  • All were of acute myeloblastic leukaemia (AML) M5-FAB type.
  • [MeSH-major] Leukemia, Myeloid, Acute / congenital

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670530.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


84. Zhang GS, Peng HL, Dai CW, Gong FJ, Xu YX, Xiao L, Pei MF, Shen JK, Yang JJ: [Acute monocytic leukemia after orthotopic liver transplantation: clinical features, molecular genetics, and significance thereof]. Zhonghua Yi Xue Za Zhi; 2005 Dec 28;85(49):3504-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute monocytic leukemia after orthotopic liver transplantation: clinical features, molecular genetics, and significance thereof].
  • OBJECTIVE: To study the clinical features and molecular genetics of acute monocytic leukemia (AML) after orthotopic liver transplantation and significance thereof.
  • METHODS: The clinical manifestations, laboratory findings, development, diagnosis, treatment, and prognosis of the first case of AML after orthotopic liver transplantation in the world, a Chinese, male, aged 46, were observed.
  • The diagnosis of chronic myelomonocytic leukemia was made.
  • Five months after the liver transplantation the disease developed to AML.
  • RT-PCR showed absence of wild type FLT3 allele.
  • At last the patient died of infection. (2) A FLT3-ITD mutation of "insertion" type was identified in the BMMCs.
  • CONCLUSION: Orthotopic liver transplantation may be complicated with acute leukemia heterogeneous in clinical features and hematology.
  • [MeSH-major] Leukemia, Monocytic, Acute / etiology. Leukemia, Monocytic, Acute / genetics. Liver Transplantation / adverse effects. Postoperative Complications

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16686070.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HSP70 Heat-Shock Proteins; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; EC 2.7.11.1 / PIM1 protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-pim-1
  •  go-up   go-down


85. Mun GI, Boo YC: Identification of CD44 as a senescence-induced cell adhesion gene responsible for the enhanced monocyte recruitment to senescent endothelial cells. Am J Physiol Heart Circ Physiol; 2010 Jun;298(6):H2102-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Senescent human umbilical vein endothelial cells (HUVECs) prepared by continuous subculturing in vitro showed higher binding affinity for monocytes (THP-1 cells, human acute monocytic leukemia cell line) compared with young cells.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20382854.001).
  • [ISSN] 1522-1539
  • [Journal-full-title] American journal of physiology. Heart and circulatory physiology
  • [ISO-abbreviation] Am. J. Physiol. Heart Circ. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD44; 0 / CD44 protein, human; 0 / RNA, Small Interfering
  •  go-up   go-down


86. Rand JH, Wu XX, Quinn AS, Chen PP, Hathcock JJ, Taatjes DJ: Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood; 2008 Sep 1;112(5):1687-95
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recognition of beta2-glycoprotein I (beta2GPI) by aPL antibodies appears to play a major role in the disease process.
  • HCQ, at concentrations of 1 mug/mL and greater, significantly reduced the binding of aPL-beta2GPI complexes to phospholipid surfaces and THP-1 (human acute monocytic leukemia cell line) monocytes.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 2007 Aug;56(8):2687-97 [17665396.001]
  • [Cites] Arthritis Rheum. 2005 May;52(5):1473-80 [15880829.001]
  • [Cites] Thromb Haemost. 1999 Oct;82(4):1376-7 [10544942.001]
  • [Cites] EMBO J. 1999 Nov 15;18(22):6228-39 [10562535.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3460-6 [10828029.001]
  • [Cites] Thromb Haemost. 2000 Sep;84(3):388-95 [11019960.001]
  • [Cites] Circulation. 2001 Feb 20;103(7):941-6 [11181467.001]
  • [Cites] Circ Res. 2002 Jan 11;90(1):29-37 [11786515.001]
  • [Cites] Thromb Haemost. 2002 Mar;87(3):518-22 [11916085.001]
  • [Cites] Lupus. 2002;11(6):356-61 [12139373.001]
  • [Cites] Rheumatology (Oxford). 2002 Aug;41(8):924-9 [12154210.001]
  • [Cites] Mol Immunol. 2002 Oct;39(5-6):299-311 [12220888.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1827-32 [12393574.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1193-200 [12937161.001]
  • [Cites] N Engl J Med. 2003 Sep 18;349(12):1133-8 [13679527.001]
  • [Cites] Drugs. 1975;9(1):19-76 [1092540.001]
  • [Cites] Thromb Res. 1982 Feb 1;25(3):219-27 [6175045.001]
  • [Cites] Prog Clin Biol Res. 1982;89:31-62 [7051035.001]
  • [Cites] Am J Med. 1988 Oct 14;85(4A):53-6 [3177431.001]
  • [Cites] Br J Clin Pharmacol. 1989 Jun;27(6):771-9 [2757893.001]
  • [Cites] J Clin Immunol. 1992 Jan;12(1):27-35 [1372614.001]
  • [Cites] Semin Arthritis Rheum. 1993 Oct;23(2 Suppl 1):82-91 [8278823.001]
  • [Cites] J Immunol. 1995 Jan 15;154(2):954-60 [7814895.001]
  • [Cites] Scand J Rheumatol. 1996;25(4):191-3 [8792794.001]
  • [Cites] Ann Rheum Dis. 2005 Sep;64(9):1321-5 [15731290.001]
  • [Cites] J Thromb Haemost. 2006 Feb;4(2):295-306 [16420554.001]
  • [Cites] JAMA. 2006 Mar 1;295(9):1050-7 [16507806.001]
  • [Cites] Nat Clin Pract Rheumatol. 2006 Sep;2(9):458-9 [16951696.001]
  • [Cites] Arthritis Rheum. 2007 May;56(5):1638-47 [17469158.001]
  • [Cites] Ann Rheum Dis. 2007 Jun;66(6):821-4 [17324970.001]
  • [Cites] Curr Rheumatol Rep. 2007 Jun;9(3):198-204 [17531172.001]
  • [Cites] Lupus. 1996 Jun;5 Suppl 1:S11-5 [8803904.001]
  • [Cites] Lupus. 1996 Jun;5 Suppl 1:S23-7 [8803906.001]
  • [Cites] Biochemistry. 1996 Oct 29;35(43):13833-42 [8901526.001]
  • [Cites] N Engl J Med. 1997 Jul 17;337(3):154-60 [9219701.001]
  • [Cites] Biochemistry. 1997 Nov 25;36(47):14384-91 [9398156.001]
  • [Cites] Circulation. 1997 Dec 16;96(12):4380-4 [9416907.001]
  • [Cites] Lupus. 1998;7(2):80-5 [9541091.001]
  • [Cites] Blood. 1998 Sep 1;92(5):1652-60 [9716593.001]
  • [Cites] Br J Haematol. 1999 Apr;105(1):102-9 [10233371.001]
  • [Cites] EMBO J. 1999 Oct 1;18(19):5166-74 [10508150.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3598-602 [15315975.001]
  • [Cites] J Thromb Haemost. 2005 May;3(5):848-53 [15869575.001]
  • [Cites] Biochem J. 2005 Aug 1;389(Pt 3):665-73 [15813706.001]
  • (PMID = 18577708.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL061331; United States / NHLBI NIH HHS / HL / HL-61331
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Anticoagulants; 0 / Antigen-Antibody Complex; 0 / Antimalarials; 0 / Lipid Bilayers; 0 / Multiprotein Complexes; 0 / Phospholipids; 0 / beta 2-Glycoprotein I; 4QWG6N8QKH / Hydroxychloroquine
  • [Other-IDs] NLM/ PMC2518879
  •  go-up   go-down


87. Gombos DS, Hungerford J, Abramson DH, Kingston J, Chantada G, Dunkel IJ, Antoneli CB, Greenwald M, Haik BG, Leal CA, Medina-Sanson A, Schefler AC, Veerakul G, Wieland R, Bornfeld N, Wilson MW, Yu CB: Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology; 2007 Jul;114(7):1378-83
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor?
  • PURPOSE: To describe a series of patients with secondary acute myelogenous leukemia (sAML) and retinoblastoma (RB).
  • MAIN OUTCOME MEASURES: History of RB and development of sAML, management of RB (surgery, radiotherapy, chemotherapy), age at diagnosis of RB and leukemia, French-American-British (FAB) subtype, and current status of patient (alive or dead).
  • Mean latent period from RB to AML diagnosis was 9.8 years (median, 42 months).
  • Nine cases were of the M2 or M5 FAB subtypes.
  • Ten children died of their leukemia.
  • CONCLUSIONS: Acute myelogenous leukemia is a rare secondary malignancy among retinoblastoma patients, many of whom were treated with primary or adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / adverse effects. Enzyme Inhibitors / adverse effects. Leukemia, Myeloid, Acute / chemically induced. Neoplasms, Second Primary / chemically induced. Podophyllotoxin / adverse effects. Retinal Neoplasms / drug therapy. Retinoblastoma / drug therapy. Topoisomerase II Inhibitors


88. Zhou B, Ju SG, Ju SW, Xie F, Zhang XG: [Establishment of human acute monocytic leukemia model in severe combined immunodeficient (SCID) mice and the analysis of pathological changes]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Jun;23(6):501-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Establishment of human acute monocytic leukemia model in severe combined immunodeficient (SCID) mice and the analysis of pathological changes].
  • AIM: To establish a model of human M5 leukemia and investigate the pathomorphological change in severe combined immunodeficient (SCID) mice after being transplanted with SHI-1 cells.
  • CONCLUSION: The SHI-1/SCID mice was constructed, which provided a useful tool to investigate acute monocytic leukemia(AML).
  • [MeSH-major] Leukemia, Monocytic, Acute / metabolism. Leukemia, Monocytic, Acute / pathology
  • [MeSH-minor] 4-1BB Ligand / metabolism. Animals. Antigens, CD14 / metabolism. Cell Line, Tumor. Disease Models, Animal. Female. Flow Cytometry. Humans. Immunohistochemistry. Mice. Mice, SCID. Random Allocation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17553342.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / 4-1BB Ligand; 0 / Antigens, CD14
  •  go-up   go-down


89. Masurier C, Boutin S, Veron P, Bernard J, Danos O, Davoust J: Enhanced lentiviral transduction of monocyte-derived dendritic cells in the presence of conditioned medium from dying monocytes. Hum Gene Ther; 2007 Feb;18(2):161-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Importantly, we found that MCM derived from a human acute monocytic leukemia cell line, THP-1, was equally effective.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17326725.001).
  • [ISSN] 1043-0342
  • [Journal-full-title] Human gene therapy
  • [ISO-abbreviation] Hum. Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media, Conditioned
  •  go-up   go-down


90. Wang ZP, Cai SX, Liu DB, Xu X, Liang HP: Anti-inflammatory effects of a novel peptide designed to bind with NF-kappaB p50 subunit. Acta Pharmacol Sin; 2006 Nov;27(11):1474-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Levels of tumor necrosis factor-alpha(TNF-alpha) and interleukin 6 (IL-6) from a human acute monocytic leukemia cell line (THP-1) treated with lipopolysaccharide (LPS) were measured using the ELISA method.
  • CONCLUSION: The peptide may have therapeutic potential for the treatment of local acute inflammation.
  • [MeSH-minor] Animals. Binding Sites. Biosensing Techniques. Cell Line, Tumor. Edema / chemically induced. Edema / pathology. Humans. Interleukin-6 / metabolism. Leukemia, Monocytic, Acute / metabolism. Leukemia, Monocytic, Acute / pathology. Mice. Mice, Inbred BALB C. Peritonitis / chemically induced. Peritonitis / pathology. Tetradecanoylphorbol Acetate. Tumor Necrosis Factor-alpha / metabolism. Zymosan

  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17049124.001).
  • [ISSN] 1671-4083
  • [Journal-full-title] Acta pharmacologica Sinica
  • [ISO-abbreviation] Acta Pharmacol. Sin.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Interleukin-6; 0 / NF-kappa B p50 Subunit; 0 / Peptides; 0 / Tumor Necrosis Factor-alpha; 9010-72-4 / Zymosan; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


91. Natarajan E, Omobono JD 2nd, Jones JC, Rheinwald JG: Co-expression of p16INK4A and laminin 5 by keratinocytes: a wound-healing response coupling hypermotility with growth arrest that goes awry during epithelial neoplastic progression. J Investig Dermatol Symp Proc; 2005 Nov;10(2):72-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have found that, in vivo, p16 is expressed by epidermal and oral keratinocytes at the migrating fronts of healing wounds and at the stromal interface of severely dysplastic and early invasive lesions and that such cells also invariably display increased expression of Laminin 5 (Lam5).
  • In culture, p16 and Lam5 are coexpressed in keratinocytes at senescence, at the edges of wounds made in confluent cultures, and when cells are plated on dishes coated with the gamma2 precursor form of Lam5 (Lam5gamma2pre).
  • Lam5/p16 coexpression in all three in vitro settings is associated with directional hypermotility and growth arrest.
  • Thus, the Lam5/p16 response is activated in normal wound healing, causing growth arrest of migratory keratinocytes that lead wound reepithelialization.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16358814.001).
  • [ISSN] 1087-0024
  • [Journal-full-title] The journal of investigative dermatology. Symposium proceedings
  • [ISO-abbreviation] J. Investig. Dermatol. Symp. Proc.
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / R01 DE013178
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / LAMC2 protein, human; 0 / Laminin; 0 / Transforming Growth Factor beta; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


92. Kuchenbauer F, Kern W, Schoch C, Kohlmann A, Hiddemann W, Haferlach T, Schnittger S: Detailed analysis of FLT3 expression levels in acute myeloid leukemia. Haematologica; 2005 Dec;90(12):1617-25
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
  • BACKGROUND AND OBJECTIVES: FLT3 mutations are found in up to 30% of cases of acute myeloid leukemia (AML).
  • Although new FLT3 mutations are being increasing by investigated, the role of FLT3 expression levels in wild type as well as in mutated FLT3 has only been infrequently addressed.
  • DESIGN AND METHODS: To further evaluate the role of FLT3 in AML we investigated FLT3 expression levels in 207 adult AML patients and 8 healthy donors by real-time polymerase chain reaction (PCR).
  • The expression levels were correlated with clinical parameters, FAB types, cytogenetics, flow cytometry, microarray analysis, FLT3 mutations, further molecular aberrations and prognosis.
  • RESULTS: FLT3 expression levels were different in certain FAB types with increasing levels in the following order: M3<M3v<M6<M2<M4eo<M4<M0<M1<M5a<M5b.
  • These results correlate with the FLT3 receptor surface expression (CD135) detected by flow cytometry (p<0.001), showing the highest CD135 expression in FAB M5.
  • Independent analysis of FLT3 expression in cytogenetic AML subgroups showed the lowest levels in t(15;17) and the highest in the t(11q23) positive AML.
  • On the molecular level, no differences in FLT3 expression levels were detected between AML with and without any FLT3 mutation as well as for FAB M5 with or without MLL abnormalities (p=0.495).
  • In patients with normal cytogenetics no impact or overall survival or event-free survival could be detected (p=0.128 and p=0.305, respectively) regardless of FLT3 muatation status, whereas investigating the group of patients with normal cytogenetics and wild-type FLT3, a clear tendency for a worse overall (p=0.059) and event free (p=0.087) survival was found.
  • Furthermore, our data indicate that FLT3 expression and signaling are closely associated with FAB M5.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Leukemia, Myeloid / enzymology. Neoplasm Proteins / biosynthesis. fms-Like Tyrosine Kinase 3 / biosynthesis
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD34 / biosynthesis. Antigens, CD34 / genetics. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Bone Marrow / pathology. Chromosome Aberrations. Disease-Free Survival. Enzyme Induction. Female. Gene Duplication. Humans. Karyotyping. Leukemia, Monocytic, Acute / genetics. Leukemia, Monocytic, Acute / pathology. Leukocyte Count. Life Tables. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Proportional Hazards Models. RNA, Messenger / biosynthesis. RNA, Messenger / metabolism. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / metabolism. Survival Analysis. Tandem Repeat Sequences

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2005 Dec;90(12):1586 [16330422.001]
  • (PMID = 16330434.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antineoplastic Agents; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


93. Villeneuve P, Kim DT, Xu W, Brandwein J, Chang H: The morphological subcategories of acute monocytic leukemia (M5a and M5b) share similar immunophenotypic and cytogenetic features and clinical outcomes. Leuk Res; 2008 Feb;32(2):269-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The morphological subcategories of acute monocytic leukemia (M5a and M5b) share similar immunophenotypic and cytogenetic features and clinical outcomes.
  • Acute monocytic leukemia (M5) is a subtype of acute myeloid leukemia (AML) with two distinct morphologic subcategories, M5a and M5b.
  • We compared the immunophenotype, cytogenetics and clinical outcome of AML M5 with non-M5 AML and also compared M5a with M5b.
  • One hundred and twelve M5 (76 M5a, 36 M5b) and 726 non-M5 cases were identified and treated on protocols at our institution.
  • There were no significant differences in immunophenotype between M5a and M5b.
  • Translocation 11q23 was the sole abnormality in 18.6% of M5 and 3.2% of non-M5 (p<0.001).
  • Trisomy 8 was also more prevalent in M5 (16.9%) than in non-M5 (8.7%; p=0.03).
  • There was no significant difference in karyotypes between M5a and M5b.
  • The complete remission rate was 70% for AML M5 and 57% for non-M5 AML (p=0.03).
  • There was no significant difference in median overall survival or disease free survival for patients with M5 versus non-M5, M5a versus M5b.
  • Our data indicate that the prognosis of AML M5 is similar to non-M5 AML and that M5a and M5b do not differ in immunophenotype, cytogenetics or clinical outcome.
  • [MeSH-major] Leukemia, Monocytic, Acute / drug therapy. Leukemia, Monocytic, Acute / genetics. Leukemia, Monocytic, Acute / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chromosome Aberrations. Cytogenetic Analysis. Disease-Free Survival. Female. Humans. Immunophenotyping. Karyotyping. Male. Middle Aged. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17689610.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


94. Hu XR, He JS, Ye XJ, Zheng WY, Wu WJ, Lin MF: Candida tropicalis arthritis in a patient with acute leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct;16(5):1215-8
MedlinePlus Health Information. consumer health - Yeast Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Candida tropicalis arthritis in a patient with acute leukemia.
  • A case of Candida tropicalis arthritis of knee occurred in a patient with acute monocytic leukemia was reported during the recovery phase of post chemotherapy myelosuppression and agranulocytosis.

  • Genetic Alliance. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Infectious Arthritis.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18928631.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down


95. Ii H, Oka M, Yamashita A, Waku K, Uozumi N, Shimizu T, Sato T, Akiba S: Inhibition of cytosolic phospholipase A(2) suppresses production of cholesteryl ester through the reesterification of free cholesterol but not formation of foam cells in oxidized LDL-stimulated macrophages. Biol Pharm Bull; 2008 Jan;31(1):6-12
Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In [(3)H]oleic acid-labeled human acute monocytic leukemia (THP-1) cell-derived macrophages (THP-M) and mouse peritoneal macrophages (MPM), which possessed at least cPLA(2)alpha and cPLA(2)gamma, stimulation with OxLDL induced the production of [(3)H]cholesteryl oleate ([(3)H]CE).The production was suppressed by an inhibitor of cPLA(2)s.
  • In cPLA(2)alpha-knockout MPM, OxLDL-induced increases in [(3)H]CE and total CE did not differ from those in wild-type MPM.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18175934.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Arachidonic Acids; 0 / Cholesterol Esters; 0 / Enzyme Inhibitors; 0 / Lipoproteins, LDL; 0 / Organophosphonates; 0 / Phospholipase A2 Inhibitors; 0 / methyl arachidonylfluorophosphonate; 0 / oxidized low density lipoprotein; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


96. Nishioka C, Ikezoe T, Yang J, Takeshita A, Taniguchi A, Komatsu N, Togitani K, Koeffler HP, Yokoyama A: Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene. Leuk Res; 2008 Jun;32(6):865-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene.
  • Activating mutations of this gene occur in nearly 30% of acute myelogenous leukemia (AML) patients.
  • In this study, we found that AZD6244 (ARRY-142886), a novel inhibitor of MEK1/2 kinases, effectively inhibited the proliferation of acute biphenotypic leukemia MV4-11 and acute monocytic leukemia MOLM13 cells.
  • Taken together, concomitant blockade of FLT3 and MEK signaling represents a promising treatment strategy for individuals with leukemia who possess activating mutations of FLT3.
  • [MeSH-major] Apoptosis / drug effects. Indoles / therapeutic use. Leukemia / pathology. MAP Kinase Kinase 1 / antagonists & inhibitors. Mitogen-Activated Protein Kinase 1 / antagonists & inhibitors. Mitogen-Activated Protein Kinase 3 / antagonists & inhibitors. Mutation / genetics. Pyrroles / therapeutic use. fms-Like Tyrosine Kinase 3 / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols. Benzimidazoles / therapeutic use. Cell Proliferation / drug effects. Female. Humans. Leukemia, Megakaryoblastic, Acute / drug therapy. Leukemia, Megakaryoblastic, Acute / genetics. Leukemia, Megakaryoblastic, Acute / pathology. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / pathology. Male. Middle Aged. Ribosomal Protein S6 Kinases, 70-kDa / antagonists & inhibitors. Ribosomal Protein S6 Kinases, 70-kDa / metabolism. Signal Transduction / drug effects. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17983653.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AZD 6244; 0 / Benzimidazoles; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib; EC 2.7.1.- / MAP2K1 protein, human; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 2.7.12.2 / MAP Kinase Kinase 1
  •  go-up   go-down


97. Sheng LX, Xie XB, Qiu GQ, Gu WY, Wang ZL, Wu HQ: [In vitro stimulation of specific antileukemia T-cell response by dendritic cells derived from CD14+ acute monocytic leukemia cells]. Ai Zheng; 2005 Nov;24(11):1338-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [In vitro stimulation of specific antileukemia T-cell response by dendritic cells derived from CD14+ acute monocytic leukemia cells].
  • BACKGROUND & OBJECTIVE: Dendritic cells (DCs) or DC-like cells had been successfully induced in vitro from leukemia cells, which may provide a promising immunotherapeutic protocol for leukemia.
  • This study was designed to investigate the efficiency of in vitro generation of dendritic cells from CD14+ acute myelomonocytic (M4) or monocytic (M5) leukemia cells and their ability of stimulating specific antileukemia T-cell response.
  • METHODS: Bone marrow mononuclear cells (BMMNCs) were isolated from 5 M4/M5 leukemia patients with high CD14 expression, and then divided into 3 groups: adherent leukemia cells, nonadherent blasts, and total unfractioned blasts.
  • When cultured with or without granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4) and tumor necrosis factor alpha (TNF-alpha) for 7-10 days, monocytic leukemia cell-derived dendritic cells (Mo-LDCs) were identified through morphologic observation and immunophenotype analysis using FCM.
  • The leukemic origin of Mo-LDCs was confirmed by chromosomal karyotype analysis combined with the aberrant expression of myeloid antigens.
  • RESULTS: The amount of CD14+ cells, which could differentiate into CD83+ mature DCs under induction of the cytokine combination, was higher in adherent leukemia cells than in nonadherent blasts and total unfractioned blasts.
  • Mo-LDCs exhibited typical morphology and phenotype as mature DCs, induced potent proliferation of homogeneous T cells in Allo-MLR, stimulated the expansion of leukemia-specific CTLs, and continued to possess the cytogenetic abnormalities of the original leukemia, as well as the aberrant expression of myeloid antigens.
  • CONCLUSIONS: In M4/M5 subtype of AML, CD14+ cells could differentiate into immune-competent Mo-LDCs under the induction of the cytokine combination.
  • CD14 expression level may predict the DCs differentiation ability of monocytic leukemia.
  • Mo-LDCs, which possess the classical phenotype and function of DCs, as well as the abnormal leukemic antigens, may be useful for the immunotherapy of M4/M5 AML.
  • [MeSH-major] Antigens, CD14 / analysis. Dendritic Cells / immunology. Leukemia, Monocytic, Acute / pathology. T-Lymphocytes, Cytotoxic / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16552959.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD14; 0 / CD83 antigen; 0 / Immunoglobulins; 0 / Membrane Glycoproteins
  •  go-up   go-down


98. Novotny JR, Nückel H, Dührsen U: Correlation between expression of CD56/NCAM and severe leukostasis in hyperleukocytic acute myelomonocytic leukaemia. Eur J Haematol; 2006 Apr;76(4):299-308

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between expression of CD56/NCAM and severe leukostasis in hyperleukocytic acute myelomonocytic leukaemia.
  • OBJECTIVE: The possible contribution of surface molecules to the development of leukostasis syndrome in hyperleukocytic acute myeloid leukaemia (AML) was assessed by routine immunophenotyping and grading of the probability of clinical leukostasis.
  • METHODS: Fifty-three patients (23 women, 30 men, median age 59 yr) with hyperleukocytic AML [white blood count (WBC) above 50 x 10(9)/L] were graded for the probability of clinical leukostasis according to the severity of neurologic, pulmonary and other symptoms possibly caused by leukostasis using a recently published scoring system.
  • RESULTS: In patients with acute monocytic leukaemia (AML M4/M5) the absolute count of leukaemic blasts expressing CD56/NCAM was highly associated with the development of symptoms graded as highly probable leukostasis and all three patients succumbing to early death were CD56 positive.
  • This was not found in AML without monocytic involvement (AML M1, M2, M3v).
  • CONCLUSIONS: The expression of CD56/NCAM, a surface marker used in routine immunophenotyping of AML, may help to predict severe and potentially fatal leukostasis in hyperleukocytic acute myelomonocytic leukaemia.
  • We extend previous findings that the mechanisms of leukostasis are different depending on the involvement of the monocytic lineage.
  • [MeSH-major] Antigens, CD56 / blood. Gene Expression Regulation, Leukemic. Leukemia, Myelomonocytic, Acute / blood. Leukostasis / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16519701.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD56
  •  go-up   go-down


99. Valmary S, Danjoux M, Delsol G, Brousset P: [Diagnostic value of anti-terminal deoxynucleotidyl transferase antibody (TdT) in hematologic pathology]. Ann Pathol; 2005 Feb;25(1):25-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic value of anti-terminal deoxynucleotidyl transferase antibody (TdT) in hematologic pathology].
  • [Transliterated title] Intérêt diagnostique de l'anticorps anti-terminal désoxynucleotidyl transférase (TdT) en pathologie hématologique.
  • AIMS: The diagnosis of primitive hematologic malignancies depends on a panel of monoclonal antibodies which is growing over time.
  • The distinction between immature (lymphoblastic lymphoma/acute lymphoblastic leukaemia) and mature lymphoma is sometimes difficult.
  • In this study, we evaluated anti-TdT antibody in the diagnosis and classification of these proliferations.
  • MATERIALS AND METHODS: 13 lesions were examined by immunohistochemistry: 4 B and T lymphoblastic lymphomas, 2 Burkitt's lymphomas, 5 B and T acute lymphoblastic leukemias and 2 acute monoblastic leukemias.
  • Significant numbers of cases of acute myeloblastic leukemias are TdT positive but could be easily distinguished from lymphoblastic proliferations.
  • CONCLUSION: Anti-TdT antibody represents a useful marker for differentiating lymphoma/acute lymphoblastic leukemia from other lymphomas.
  • This marker, available in routine diagnosis should be systematically included in the panel of antibodies used for immunophenotyping hematologic malignancies.
  • [MeSH-major] Antibodies. DNA Nucleotidylexotransferase / analysis. DNA Nucleotidylexotransferase / immunology. Hematologic Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Burkitt Lymphoma / diagnosis. Child. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Immunophenotyping. Leukemia, Monocytic, Acute / diagnosis. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, T-Cell / diagnosis. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15981929.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies; EC 2.7.7.31 / DNA Nucleotidylexotransferase
  •  go-up   go-down


100. Wang YF, Song QS, Zhang YM, Ma DL, Wang Y, Ke XY: [Sensitizing effect of recombinant human PDCD5 protein on chemotherapy of acute monocytic leukemia cell line U937 and its mechanism]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr;18(2):277-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sensitizing effect of recombinant human PDCD5 protein on chemotherapy of acute monocytic leukemia cell line U937 and its mechanism].
  • Hochst 33258 staining was used to observe morphology of the apoptotic cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20416151.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Apoptosis Regulatory Proteins; 0 / Neoplasm Proteins; 0 / PDCD5 protein, human; 0 / Recombinant Proteins; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3
  •  go-up   go-down






Advertisement